Author: "Canonica, Giorgio" / Database: OpenAIRE - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Canonica, Giorgio"' showing total 242 results

Start Over Author "Canonica, Giorgio" Database OpenAIRE

242 results on '"Canonica, Giorgio"'

1. Additional file 3 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Author: Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, and Schroeder, Jan Walter
Abstract: Additional file 3: Table S3. Asthma-related healthcare resource utilization during benralizumab treatment. Data are expressed as mean ± SD.
Published: 2023
Full Text: View/download PDF

2. Additional file 4 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Author: Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, and Schroeder, Jan Walter
Abstract: Additional file 4: Table S4. Patients achieving MCID in ACT total score during benralizumab treatment. Data are reported as number and percentage of patients achieving MCID.
Published: 2023
Full Text: View/download PDF

3. Additional file 1 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Author: Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, and Schroeder, Jan Walter
Abstract: Additional file 1: Table S1. Patients disposition. Data are expressed as N. Percentages computed over the total number of enrolled patients. Percentages computed out of the number of eligible patients.
Published: 2023
Full Text: View/download PDF

4. Additional file 5 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Author: Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, and Schroeder, Jan Walter
Abstract: Additional file 5: Table S5. Socio-demographic, clinical and laboratory characteristics, data on prior asthma medication, exacerbations, lung function, ACT score of naïve and bio-experienced patients, collected before initiating benralizumab treatment. Data were collected at the index date or during the 12 months prior to the index date and are expressed as N, mean ± SD, or median. Unless otherwise stated, data are related to N = 124 naïve patients and N = 38 bio-experienced patients. Data are expressed as N, mean ± SD, or median. Unless otherwise stated, the evaluable population included 124 naïve patients and N = 38 bio-experienced patients.
Published: 2023
Full Text: View/download PDF

5. Additional file 2 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Author: Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, and Schroeder, Jan Walter
Abstract: Additional file 2: Table S2. Additional information related to maintenance asthma treatments, positivity to perennial allergens, comorbidities and OCS-related conditions collected before initiating benralizumab treatment. Data were collected at the index date or during the 12 months prior to the index date and are expressed as N, mean ± SD, or median. Unless otherwise stated, the evaluable population included 162 patients.
Published: 2023
Full Text: View/download PDF

6. OCS Tapering Delphi

Author: Suehs, Carey, Price, David, Menzies-gow, Andrew, Canonica, Giorgio, Gurnell, Mark, and Bourdin, Arnaud
Subjects: stomatognathic diseases, immune system diseases, education, hormones, hormone substitutes, and hormone antagonists, respiratory tract diseases
Abstract: Expert statements concerning the tapering of oral corticosteroids (OCS) for the treatment of asthma
Published: 2022
Full Text: View/download PDF

7. Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis

Author: Caruso, Cristiano, Cameli, Paolo, Altieri, Elena, Aliani, Maria, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Canonica, Giorgio Walter, Centanni, Stefano, D'Amato, Maria, Del Giacco, Stefano, De Michele, Fausto, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Caminati, Marco, Vultaggio, Alessandra, Zullo, Alessandro, Rizzoli, Sara, Boarino, Silvia, Vitiello, Gianfranco, Menzella, Francesco, and Di Marco, Fabiano
Subjects: benralizumab, Settore MED/10, biologics, observational, severe eosinophilic asthma, switch, General Medicine
Abstract: BackgroundSevere asthma is a heterogeneous inflammatory disease driven by eosinophilic inflammation in the majority of cases. Despite biologic therapy patients may still be sub-optimally controlled, and the choice of the best biologic is a matter of debate. Indeed, switching between biologics is common, but no official guidelines are available and real-world data are limited.Materials and methodsIn this post hoc analysis of the Italian, multi-center, observational, retrospective study, ANANKE. Patients with severe eosinophilic asthma treated with benralizumab were divided in two groups based on history of previous biologic therapy (biologic-experienced [suboptimal response] vs naïve). Baseline clinical and laboratory characteristics were collected in the 12 months prior to benralizumab treatment. Change over time in blood eosinophils, annualized exacerbation rate (AER), asthma control (ACT), lung function and oral corticosteroid (OCS) use following benralizumab initiation were collected in the two groups.ResultsA total of 147 biologic-naïve and 58 biologic-experienced (34 omalizumab, 19 mepolizumab, and 5 omalizumab-mepolizumab) patients were enrolled. Biologic-experienced patients were more likely to be atopic and have a higher AER despite more frequent OCS use. Similar reductions in AER (>90% in both groups), OCS use (≥49% reduction in dosage and ≥41% able to eliminate OCS), ACT improvement (≥7 points gained in 48 weeks) and lung function (≥300 mL of FEV1 improvement in 48 weeks) were observed after benralizumab introduction within the two groups. There were no registered discontinuations of benralizumab for safety reasons.ConclusionIn this post hoc analysis, patients who were switched to benralizumab because of suboptimal control with a previous biologic therapy were more likely to be atopic and more often treated with omalizumab. Benralizumab is effective in both naïve patients and those previously treated with a biologic.
Published: 2022

8. OCS Tapering Delphi

Author: Suehs, Carey, Price, David, Menzies-gow, Andrew, Canonica, Giorgio, Gurnell, Mark, Bleecker, Eugene, and Bourdin, Arnaud
Subjects: stomatognathic diseases, immune system diseases, education, hormones, hormone substitutes, and hormone antagonists, respiratory tract diseases
Abstract: Expert statements concerning the tapering of oral corticosteroids (OCS) for the treatment of asthma
Published: 2022
Full Text: View/download PDF

9. A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma

Author: Menzies-Gow, Andrew, Jackson, David J., Al-Ahmad, Mona, Bleecker, Eugene R., Cosio Piqueras, Francisco de Borja G., Brunton, Stephen, Canonica, Giorgio Walter, Chan, Charles K.N., Haughney, John, Holmes, Steve, Kocks, Janwillem, Winders, Tonya, and Groningen Research Institute for Asthma and COPD (GRIAC)
Subjects: Severe asthma, Health care, Patient advocacy, Humans, COVID-19, Pharmacology (medical), General Medicine, Patient Care, Pandemics, Referral and Consultation, Asthma
Abstract: Asthma is a heterogenous respiratory disease, usually associated with chronic airway inflammation and hyper-responsiveness, which affects an estimated 339 million people worldwide. Severe asthma affects approximately 5–10% of patients with asthma, approximately 17–34 million people globally, more than half of whom have uncontrolled disease. Severe asthma carries a substantial burden of disease, including unpredictable symptoms and potentially life-threatening flare-ups. Furthermore, severe asthma has a substantial burden on health care systems and economies worldwide. In 2018, a group of experts from the clinical community, patient support groups, and professional organisations joined together to develop the Severe Asthma Patient Charter, which set out six principles to define what patients should expect for the management of their severe asthma and what should constitute a basic standard of care. Since the publication of that original Charter in 2018, several important changes have occurred, including an improved understanding of asthma and effective asthma management; several new therapies have become available; and finally, the COVID-19 pandemic has placed a spotlight on respiratory conditions, the workforces that treat them, and the fundamental importance of health care system resilience. With those developments in mind, we, representatives of the academic, clinical, and patient advocacy group communities, have updated the Charter to Improve Patient Care in Severe Asthma with a focus on six principles: (1) I deserve a timely, comprehensive assessment of my asthma and its severity; (2) I deserve a timely, straightforward referral to an appropriate specialist for my asthma when it is not well controlled; (3) I deserve to understand what makes my asthma worse; (4) I deserve access to treatment and care that reduces the impact of asthma on my daily life; (5) I deserve not to be reliant on systemic corticosteroids; (6) I deserve to be involved in decisions about my treatment and care.
Published: 2022

10. Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis

Author: D'Amato, Maria, Menzella, Francesco, Altieri, Elena, Bargagli, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, De Michele, Fausto, Di Marco, Fabiano, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Vultaggio, Alessandra, Ori, Alessandra, Simoni, Lucia, Boarino, Silvia, Vitiello, Gianfranco, Aliani, Maria, and Del Giacco, Stefano
Subjects: benralizumab, biologics, chronic rhinosinusitis with nasal polyps, observational, severe eosinophilic asthma, Settore MED/10
Abstract: BackgroundSevere eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive eosinophilic inflammation. Post-hoc analyses from a pivotal clinical trial have demonstrated the enhanced efficacy of benralizumab on asthma outcomes in patients with CRSwNP as a comorbidity.MethodsThis is a post-hoc analysis from the Italian multi-center observational retrospective ANANKE study. Patients were divided into two groups based on self-reported CRSwNP. Baseline clinical and laboratory features in the 12 months prior to benralizumab prescription were collected. Data of change over time of blood eosinophils, annualized exacerbations rates (AER), asthma control, lung function, oral corticosteroids (OCS) use, and benralizumab discontinuation were collected during the observation period.ResultsAt baseline, the 110 patients with CRSwNP were less frequently female (50.9% vs 74.2%) and obese (9.1% vs. 22.6%) with higher eosinophils (605 vs. 500 cells/mm3) and OCS use when compared to patients without CRSwNP. Similar reductions of AER were seen (-95.8% vs. −91.5% for any exacerbation and −99.1% vs. −92.2% for severe exacerbations in patients with and without CRSwNP, respectively). During benralizumab treatment, comorbid SEA+CRSwNP was associated with a lower risk of any exacerbation (p = 0.0017) and severe exacerbations (p = 0.025). After a mean ± SD exposure of 10.3 ± 5.0 months, half of the SEA+CRSwNP patients eliminated OCS use. No discontinuation for safety reasons was recorded.ConclusionsThis study helped to confirm the baseline clinical features that distinguish patients with and without CRSwNP being prescribed benralizumab. Numerically enhanced OCS reduction and lower exacerbation risk were observed in patients with SEA and comorbid CRSwNP treated with benralizumab.
Published: 2022

11. Additional file 5 of ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

Author: Menzella, Francesco, Bargagli, Elena, Aliani, Maria, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Caruso, Cristiano, Centanni, Stefano, D��Amato, Maria, Del Giacco, Stefano, De Michele, Fausto, Di Marco, Fabiano, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Vultaggio, Alessandra, Simoni, Lucia, Ori, Alessandra, Boarino, Silvia, Vitiello, Gianfranco, Altieri, Elena, and Canonica, Giorgio Walter
Abstract: Additional file 5: Table S1. Patient characteristics recorded before the start of benralizumab therapy. Data are N (%), mean��SD, or median (IQR). Unless otherwise specified, the evaluable populations included 85 allergic and 120 non-allergic patients.
Published: 2022
Full Text: View/download PDF

12. Additional file 6 of ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

Author: Menzella, Francesco, Bargagli, Elena, Aliani, Maria, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Caruso, Cristiano, Centanni, Stefano, D��Amato, Maria, Del Giacco, Stefano, De Michele, Fausto, Di Marco, Fabiano, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Vultaggio, Alessandra, Simoni, Lucia, Ori, Alessandra, Boarino, Silvia, Vitiello, Gianfranco, Altieri, Elena, and Canonica, Giorgio Walter
Abstract: Additional file 6: Table S2. Evaluable patients with data on OCS use at the index date and at enrolment are 14 for allergic and 30 for non-allergic subjects. OCS dose is indicated as a median (IQR).
Published: 2022
Full Text: View/download PDF

13. Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study

Author: Suehs, Carey M, Menzies-Gow, Andrew, Price, David, Bleecker, Eugene R, Canonica, Giorgio Walter, Gurnell, Mark, Bourdin, Arnaud, Panel, Oral Corticosteroids Tapering Delphi Expert, Suehs, Carey M [0000-0002-2175-3496], Menzies-Gow, Andrew [0000-0001-9707-4986], Price, David [0000-0002-9728-9992], Bleecker, Eugene R [0000-0002-4767-3494], Canonica, Giorgio Walter [0000-0001-8467-2557], Gurnell, Mark [0000-0001-5745-6832], Bourdin, Arnaud [0000-0002-4645-5209], and Apollo - University of Cambridge Repository
Subjects: Adult, Male, Consensus, Delphi Technique, shared decision-making, Administration, Oral, Middle Aged, Asthma, Drug Administration Schedule, biological treatments, Adrenal Cortex Hormones, Practice Guidelines as Topic, adverse effects, Humans, Female, adrenal insufficiency, Expert Testimony
Abstract: Rationale: There is a need to minimize oral corticosteroid (OCS) use in patients with asthma to prevent their costly and burdensome adverse effects. Current guidelines do not provide recommendations for OCS tapering in patients with asthma.Objectives: To develop expert consensus on OCS tapering among international experts.Methods: A modified Delphi method was used to develop expert consensus statements relating to OCS use, tapering, adverse effects, adrenal insufficiency, and patient-physician shared decision-making. Initial statements proposed by experts were categorized, filtered for repetition, and presented back to experts over three ranking rounds to obtain consensus (≥70% agreement).Measurements and Main Results: One hundred thirty-one international experts participated in the study, and 296 statements were ranked. Numerous recommendations and guidance regarding appropriate OCS use were established. Experts agreed that OCS tapering should be attempted in all patients with asthma receiving maintenance OCS therapy, with personalization of tapering rhythm and speed. The importance of recognizing individual adverse effects was also established; however, a unified approach to the assessment of adrenal insufficiency was not reached. Shared decision-making was considered an important goal during the tapering process.Conclusions: In this Delphi study, expert consensus statements were generated on OCS use, tapering, adverse-effect screening, and shared decision-making, which may be used to inform clinical practice. Areas of nonconsensus were identified, highlighting uncertainty among the experts around some aspects of OCS use in asthma, such as adrenal insufficiency, which underscores the need for further research in these domains.
Published: 2021

14. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Author: Harrison, Tim W, Chanez, Pascal, Menzella, Francesco, Canonica, Giorgio Walter, Louis, Renaud, Cosio, Borja G, Lugogo, Njira L, Mohan, Arjun, Burden, Annie, McDermott, Lawrence, Garcia Gil, Esther, Zangrilli, James G, Wolfgang Pohl, Robert Voves, Maud Deschampheleire, Renaud Louis, Jean-Benoit Martinot, Rudi Peché, Kenneth Chapman, Amarjit Cheema, Delbert Dorscheid, J Mark FitzGerald, Remi Gagnon, William Patrick Killorn, Ronald Olivenstein, George Philteos, Clare Ramsey, J Douglass Rolf, Brandie Walker, Ole Hilberg, Tina Skjold, Ingrid Titlestad, Auli Hakulinen, Maritta Kilpeläinen, Michèle Ben Hayoun, Philippe Bonniaud, Arnaud Bourdin, Pascal Chanez, Frédéric De Blay, Gaëtan Deslee, Gilles Devouassoux, Alain Didier, Youcef Douadi, Stéphanie Fry, Gilles Garcia, Pierre-Olivier Girodet, Christophe Leroyer, Antoine Magnan, Guillaume Mahay, Cécilia Nocent, Christophe Pison, Pauline-Marie Roux, Camille Taillé, Juliana-Angelica Tiotiu, Ekkehard Beck, Margret Jandl, Christian Kaehler, Frank Kässner, Frank Koesters, Juliane Kronsbein, Thomas Schaum, Christian Schulz, Dirk Skowasch, Christian Taube, Tobias Welte, Andrés de Roux, Bianca Beghé, Francesco Blasi, Giorgio Walter Canonica, Giovanna Carpagnano, Cristiano Caruso, Angelo Guido Corsico, Elio Constantino, Nunzio Crimi, Piero Maestrelli, Francesco Menzella, Manlio Milanese, Alberto Papi, Girolamo Pelaia, Laura Pini, Pierachille Santus, Eleonora Savi, Nicola Scichilone, Gianenrico Senna, Giuseppe Spadaro, Adriano Vaghi, Steven Gans, Jurgen Hölters, B Langeveld, Willem Pieters, G H A Staaks, Ilonka van Veen, J W K van den Berg, Gunnar Einvik, Sverre Lehmann, Ismael Ali García, Carlos Almonacid, Irina Bobolea, Paloma Campo Mozo, Gustavo de Luiz, Christian Domingo Ribas, José María Echave-Sustaeta María-Tomé, Juan Luis García Rivero, Borja García-Cosío Piqueras, Ana Gómez-Bastero Fernández, Ruperto González Pérez, Aythamy Henríquez Santa, Carlos Martínez Rivera, Xavier Muñoz Gall, Jacinto Ramos, Jose Gregorio Soto Campos, Carmen Vidal Pan, Nikolai Stenfors, Alf Tunsäter, Ines Vinge, Rekha Chaudhuri, Timothy Harrison, Adel Mansur, Shuaib Nasser, Monica Nordstrom, Paul Pfeffer, Dinesh Saralaya, Philip Short, Arun Adlakha, Oral Alpan, Francis Averill, Anil Badhwar, Jose Bardelas, Barbara Baxter, George Bensch, William Berger, Jonathan Bernstein, Tracy Bridges, Ryan Brimeyer, William Calhoun, Edward Campbell, William Brett Cherry, Geoffrey Chupp, Lee Clore, John Cohn, Jeremy Cole, John Condemi, James Cury, Benjamin Davis, Samuel DeLeon, Luis Delacruz, Joseph Diaz, David Erb, Emeka Eziri, Faisal Fakih, Douglas Fiedler, David Fost, Stephen Fritz, Erika Gonzalez, Brad Goodman, Peter Gottlieb, Gregory Gottschlich, Richard Gower, Rizan Hajal, James Harris, Hengameh Heidarian-Raissy, Albrecht Heyder, David Hill, Fernando Holguin, Iftikhar Hussain, Jonathan Illowite, Joshua Jacobs, Mikell Jarratt, Harold Kaiser, Neil Kao, Ravindra Kashyap, David Kaufman, Edward Kent, Kenneth Kim, Ryan Klein, Monica Kraft, Ritsu Kono, Shahrukh Kureishy, Jeffrey Leflein, Mila Leong, Huamin Li, Robert Lin, Njira Lugogo, Michael Marcus, Diego Jose Maselli Caceres, Vinay Mehta, Curtis Mello, Mark Millard, Aaron Milstone, Arjun Mohan, Wendy Moore, Mark Moss, Nayla Mumneh, Thomas O'Brien, David Ostransky, Michael Palumbo, Purvi Parikh, Sudhir Parikh, Amit Patel, Guido Perez, Warren Pleskow, Bruce Prenner, Dileep Puppala, John Ramey, Joan Reibman, Ramon Reyes, Emory Robinette, Ileana Rodicio, Stephen Ryan, Sudhir Sekhsaria, Barry Sigal, Vinay Sikand, Weily Soong, Selwyn Spangenthal, Roy St John, Gary Steven, Vijay Subramaniam, Kaharu Sumino, Eric Sztejman, Ricardo A Tan, Tonny Tanus, Charles Thompson, Carl Thornblade, Manuel Villareal, Sally Wenzel, Heidi Zafra, Tomasz Ziedalski, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL), Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Tim W, Harrison, Pascal, Chanez, Francesco, Menzella, Giorgio Walter, Canonica, Renaud, Loui, Borja G, Cosio, Njira L, Lugogo, Arjun, Mohan, Annie, Burden, Lawrence, Mcdermott, Esther, Garcia Gil, Zangrilli, G, Jame, Pohl, Wolfgang, Voves, Robert, Deschampheleire, Maud, Louis, Renaud, Martinot, Jean-Benoit, Peché, Rudi, Chapman, Kenneth, Cheema, Amarjit, Dorscheid, Delbert, Mark FitzGerald, J, Gagnon, Remi, Patrick Killorn, William, Olivenstein, Ronald, Philteos, George, Ramsey, Clare, Douglass Rolf, J, Walker, Brandie, Hilberg, Ole, Skjold, Tina, Titlestad, Ingrid, Hakulinen, Auli, Kilpeläinen, Maritta, Ben Hayoun, Michèle, Bonniaud, Philippe, Bourdin, Arnaud, Chanez, Pascal, De Blay, Frédéric, Deslee, Gaëtan, Devouassoux, Gille, Didier, Alain, Douadi, Youcef, Fry, Stéphanie, Garcia, Gille, Girodet, Pierre-Olivier, Leroyer, Christophe, Magnan, Antoine, Mahay, Guillaume, Nocent, Cécilia, Pison, Christophe, Roux, Pauline-Marie, Taillé, Camille, Tiotiu, Juliana-Angelica, Beck, Ekkehard, Jandl, Margret, Kaehler, Christian, Kässner, Frank, Koesters, Frank, Kronsbein, Juliane, Schaum, Thoma, Schulz, Christian, Skowasch, Dirk, Taube, Christian, Welte, Tobia, de Roux, André, Beghé, Bianca, Blasi, Francesco, Walter Canonica, Giorgio, Carpagnano, Giovanna, Caruso, Cristiano, Guido Corsico, Angelo, Constantino, Elio, Crimi, Nunzio, Maestrelli, Piero, Menzella, Francesco, Milanese, Manlio, Papi, Alberto, Pelaia, Girolamo, Pini, Laura, Santus, Pierachille, Savi, Eleonora, Scichilone, Nicola, Senna, Gianenrico, Spadaro, Giuseppe, Vaghi, Adriano, Gans, Steven, Hölters, Jurgen, Langeveld, B, Pieters, Willem, A Staaks, G H, van Veen, Ilonka, K van den Berg, J W, Einvik, Gunnar, Lehmann, Sverre, Ali García, Ismael, Almonacid, Carlo, Bobolea, Irina, Campo Mozo, Paloma, de Luiz, Gustavo, Domingo Ribas, Christian, María Echave-Sustaeta María-Tomé, José, Luis García Rivero, Juan, García-Cosío Piqueras, Borja, Gómez-Bastero Fernández, Ana, González Pérez, Ruperto, Henríquez Santa, Aythamy, Martínez Rivera, Carlo, Muñoz Gall, Xavier, Ramos, Jacinto, Gregorio Soto Campos, Jose, Vidal Pan, Carmen, Stenfors, Nikolai, Tunsäter, Alf, Vinge, Ine, Chaudhuri, Rekha, Harrison, Timothy, Mansur, Adel, Nasser, Shuaib, Nordstrom, Monica, Pfeffer, Paul, Saralaya, Dinesh, Short, Philip, Adlakha, Arun, Alpan, Oral, Averill, Franci, Badhwar, Anil, Bardelas, Jose, Baxter, Barbara, Bensch, George, Berger, William, Bernstein, Jonathan, Bridges, Tracy, Brimeyer, Ryan, Calhoun, William, Campbell, Edward, Brett Cherry, William, Chupp, Geoffrey, Clore, Lee, Cohn, John, Cole, Jeremy, Condemi, John, Cury, Jame, Davis, Benjamin, Deleon, Samuel, Delacruz, Lui, Diaz, Joseph, Erb, David, Eziri, Emeka, Fakih, Faisal, Fiedler, Dougla, Fost, David, Fritz, Stephen, Gonzalez, Erika, Goodman, Brad, Gottlieb, Peter, Gottschlich, Gregory, Gower, Richard, Hajal, Rizan, Harris, Jame, Heidarian-Raissy, Hengameh, Heyder, Albrecht, Hill, DAVID STANLEY, Holguin, Fernando, Hussain, Iftikhar, Illowite, Jonathan, Jacobs, Joshua, Jarratt, Mikell, Kaiser, Harold, Kao, Neil, Kashyap, Ravindra, Kaufman, David, Kent, Edward, Kim, Kenneth, Klein, Ryan, Kraft, Monica, Kono, Ritsu, Kureishy, Shahrukh, Leflein, Jeffrey, Leong, Mila, Li, Huamin, Lin, Robert, Lugogo, Njira, Marcus, Michael, Jose Maselli Caceres, Diego, Mehta, Vinay, Mello, Curti, Millard, Mark, Milstone, Aaron, Mohan, Arjun, Moore, Wendy, Moss, Mark, Mumneh, Nayla, O'Brien, Thoma, Ostransky, David, Palumbo, Michael, Parikh, Purvi, Parikh, Sudhir, Patel, Amit, Perez, Guido, Pleskow, Warren, Prenner, Bruce, Puppala, Dileep, Ramey, John, Reibman, Joan, Reyes, Ramon, Robinette, Emory, Rodicio, Ileana, Ryan, Stephen, Sekhsaria, Sudhir, Sigal, Barry, Sikand, Vinay, Soong, Weily, Spangenthal, Selwyn, St John, Roy, Gary, Steven, Subramaniam, Vijay, Sumino, Kaharu, Sztejman, Eric, A Tan, Ricardo, Tanus, Tonny, Thompson, Charle, Thornblade, Carl, Villareal, Manuel, Wenzel, Sally, Zafra, Heidi, Ziedalski, Tomasz, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de pneumologie, Harrison T.W., Chanez P., Menzella F., Canonica G.W., Louis R., Cosio B.G., Lugogo N.L., Mohan A., Burden A., McDermott L., Garcia Gil E., Zangrilli J.G., Pohl W., Voves R., Deschampheleire M., Martinot J.-B., Peche R., Chapman K., Cheema A., Dorscheid D., FitzGerald J.M., Gagnon R., Killorn W.P., Olivenstein R., Philteos G., Ramsey C., Rolf J.D., Walker B., Hilberg O., Skjold T., Titlestad I., Hakulinen A., Kilpelainen M., Ben Hayoun M., Bonniaud P., Bourdin A., De Blay F., Deslee G., Devouassoux G., Didier A., Douadi Y., Fry S., Garcia G., Girodet P.-O., Leroyer C., Magnan A., Mahay G., Nocent C., Pison C., Roux P.-M., Taille C., Tiotiu J.-A., Beck E., Jandl M., Kaehler C., Kassner F., Koesters F., Kronsbein J., Schaum T., Schulz C., Skowasch D., Taube C., Welte T., de Roux A., Beghe B., Blasi F., Carpagnano G., Caruso C., Corsico A.G., Constantino E., Crimi N., Maestrelli P., Milanese M., Papi A., Pelaia G., Pini L., Santus P., Savi E., Scichilone N., Senna G., Spadaro G., Vaghi A., Gans S., Holters J., Langeveld B., Pieters W., Staaks G.H.A., van Veen I., van den Berg J.W.K., Einvik G., Lehmann S., Ali Garcia I., Almonacid C., Bobolea I., Campo Mozo P., de Luiz G., Domingo Ribas C., Echave-Sustaeta Maria-Tome J.M., Garcia Rivero J.L., Garcia-Cosio Piqueras B., Gomez-Bastero Fernandez A., Gonzalez Perez R., Henriquez Santa A., Martinez Rivera C., Munoz Gall X., Ramos J., Gregorio Soto Campos J., Vidal Pan C., Stenfors N., Tunsater A., Vinge I., Chaudhuri R., Harrison T., Mansur A., Nasser S., Nordstrom M., Pfeffer P., Saralaya D., Short P., Adlakha A., Alpan O., Averill F., Badhwar A., Bardelas J., Baxter B., Bensch G., Berger W., Bernstein J., Bridges T., Brimeyer R., Calhoun W., Campbell E., Cherry W.B., Chupp G., Clore L., Cohn J., Cole J., Condemi J., Cury J., Davis B., DeLeon S., Delacruz L., Diaz J., Erb D., Eziri E., Fakih F., Fiedler D., Fost D., Fritz S., Gonzalez E., Goodman B., Gottlieb P., Gottschlich G., Gower R., Hajal R., Harris J., Heidarian-Raissy H., Heyder A., Hill D., Holguin F., Hussain I., Illowite J., Jacobs J., Jarratt M., Kaiser H., Kao N., Kashyap R., Kaufman D., Kent E., Kim K., Klein R., Kraft M., Kono R., Kureishy S., Leflein J., Leong M., Li H., Lin R., Lugogo N., Marcus M., Maselli Caceres D.J., Mehta V., Mello C., Millard M., Milstone A., Moore W., Moss M., Mumneh N., O'Brien T., Ostransky D., Palumbo M., Parikh P., Parikh S., Patel A., Perez G., Pleskow W., Prenner B., Puppala D., Ramey J., Reibman J., Reyes R., Robinette E., Rodicio I., Ryan S., Sekhsaria S., Sigal B., Sikand V., Soong W., Spangenthal S., St. John R., Steven G., Subramaniam V., Sumino K., Sztejman E., Tan R.A., Tanus T., Thompson C., Thornblade C., Villareal M., Wenzel S., Zafra H., Ziedalski T., and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Pulmonary and Respiratory Medicine, Spirometry, Adult, Male, medicine.medical_specialty, Exacerbation, [SDV]Life Sciences [q-bio], Population, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Placebo, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Humans, 030212 general & internal medicine, Anti-Asthmatic Agents, Patient Reported Outcome Measures, education, Sinusitis, Asthma, education.field_of_study, medicine.diagnostic_test, business.industry, Middle Aged, medicine.disease, Benralizumab, 3. Good health, Eosinophils, 030228 respiratory system, chemistry, Asthma Control Questionnaire, Disease Progression, Quality of Life, Female, business
Abstract: Background: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms. Methods: This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18–75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional controllers, screening blood eosinophil counts of at least 150 cells per μL, and an Asthma Control Questionnaire 6 (ACQ-6) score of 1·5 or more. Patients who met eligibility criteria were randomly assigned (2:1; stratified by previous exacerbation count [two, or three or more], maintenance oral corticosteroid use, and region), using an integrated web-based response system, to receive benralizumab at 30 mg every 8 weeks (first three doses given 4 weeks apart) or matched placebo for 24 weeks. Primary efficacy measure was annualised asthma exacerbation rate, with rate ratio (RR) calculated over the approximate 24-week follow-up. Secondary efficacy measures included change from baseline to end of treatment (week 24) in St George's Respiratory Questionnaire (SGRQ) total score (key secondary endpoint), FEV1, peak expiratory flow (PEF), ACQ-6, Predominant Symptom and Impairment Assessment (PSIA), Clinician Global Impression of Change (CGI-C), Patient Global Impression of Change (PGI-C), and Sino-Nasal Outcome Test-22 (SNOT-22). All efficacy analyses, except for SNOT-22, were summarised and analysed using the full analysis set on an intention-to-treat population (all randomly assigned patients receiving investigational product, regardless of protocol adherence or continued participation in the study). SNOT-22 was summarised for the subgroup of patients with physician-diagnosed nasal polyposis with informed consent. This study is registered with ClinicalTrials.gov, NCT03170271. Findings: Between July 7, 2017, and Sept 25, 2019, 656 patients received benralizumab (n=427) or placebo (n=229). Baseline characteristics were consistent with severe eosinophilic asthma. Benralizumab significantly reduced exacerbation risk by 49% compared with placebo (RR estimate 0·51, 95% CI 0·39–0·65; p5%) were nasopharyngitis (30 [7%]), headache (37 [9%]), sinusitis (28 [7%]), bronchitis (22 [5%]), and pyrexia (26 [6%]). Fewer serious adverse events were reported for benralizumab (23 [5%]) versus placebo (25 [11%]), and the only common serious adverse event (experienced by >1% of patients) was worsening of asthma, which was reported for nine (2%) patients in the benralizumab group and nine (4%) patients in the placebo group. Interpretation: Our results extend the efficacy profile of benralizumab for patients with severe eosinophilic asthma, showing early clinical benefits in patient-reported outcomes, HRQOL, lung function, and nasal polyposis symptoms. Funding: AstraZeneca.
Published: 2021

15. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

Author: Heaney, Liam G., Perez de Llano, Luis, Al-Ahmad, Mona, Backer, Vibeke, Busby, John, Canonica, Giorgio Walter, Christoff, George C., Cosio, Borja G., FitzGerald, J. Mark, Heffler, Enrico, Iwanaga, Takashi, Jackson, David J., Menzies-Gow, Andrew N., Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Pfeffer, Paul E., Popov, Todor A., Porsbjerg, Celeste M., Rhee, Chin Kook, Sadatsafavi, Mohsen, Tohda, Yuji, Wang, Eileen, Wechsler, Michael E., Alacqua, Marianna, Altraja, Alan, Bjermer, Leif, Björnsdóttir, Unnur S., Bourdin, Arnaud, Brusselle, Guy G., Buhl, Roland, Costello, Richard W., Hew, Mark, Koh, Mariko Siyue, Lehmann, Sverre, Lehtimäki, Lauri, Peters, Matthew, Taillé, Camille, Taube, Christian, Tran, Trung N., Zangrilli, James, Bulathsinhala, Lakmini, Carter, Victoria A., Chaudhry, Isha, Eleangovan, Neva, Hosseini, Naeimeh, Kerkhof, Marjan, Murray, Ruth B., Price, Chris A., Price, David B., Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Epidemiology, Tampere University, Department of Respiratory medicine, Dermatology and Allergology, and Clinical Medicine
Subjects: PROTOCOL, Adult, Male, Asia, [SDV]Life Sciences [q-bio], Medizin, 3121 Internal medicine, Global Health, Severity of Illness Index, VALIDATION, International Severe Asthma Registry, MECHANISMS, Cohort Studies, Leukocyte Count, Middle East, Adrenal Cortex Hormones, Eosinophilia, Medicine and Health Sciences, Prevalence, Humans, Anti-Asthmatic Agents, Registries, Age of Onset, PREDICTORS, ComputingMilieux_MISCELLANEOUS, RECEPTOR, BENRALIZUMAB, Middle Aged, Asthma, Patient Care Management, Respiratory Function Tests, Eosinophils, Europe, Biological Variation, Population, North America, Female, FENO
Abstract: Background: Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe asthma cohorts. Research Question: What is the prevalence of eosinophilic and noneosinophilic phenotypes in the population with severe asthma, and can these phenotypes be differentiated by clinical and biomarker variables? Study Design and Methods: This was an historical registry study. Adult patients with severe asthma and available blood eosinophil count (BEC) from 11 countries enrolled in the International Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized according to likelihood of eosinophilic phenotype using a predefined gradient eosinophilic algorithm based on highest BEC, long-term oral corticosteroid use, elevated fractional exhaled nitric oxide, nasal polyps, and adult-onset asthma. Demographic and clinical characteristics were defined at baseline (ie, 1 year before or closest to date of BEC). Results: One thousand seven hundred sixteen patients with prospective data were included; 83.8% were identified as most likely (grade 3), 8.3% were identified as likely (grade 2), and 6.3% identified as least likely (grade 1) to have an eosinophilic phenotype, and 1.6% of patients showed a noneosinophilic phenotype (grade 0). Eosinophilic phenotype patients (ie, grades 2 or 3) showed later asthma onset (29.1 years vs 6.7 years; P < .001) and worse lung function (postbronchodilator % predicted FEV1, 76.1% vs 89.3%; P = .027) than those with a noneosinophilic phenotype. Patients with noneosinophilic phenotypes were more likely to be women (81.5% vs 62.9%; P = .047), to have eczema (20.8% vs 8.5%; P = .003), and to use anti-IgE (32.1% vs 13.4%; P = .004) and leukotriene receptor antagonists (50.0% vs 28.0%; P = .011) add-on therapy. Interpretation: According to this multicomponent, consensus-driven, and evidence-based eosinophil gradient algorithm (using variables readily accessible in real life), the severe asthma eosinophilic phenotype was more prevalent than previously identified and was phenotypically distinct. This pragmatic gradient algorithm uses variables readily accessible in primary and specialist care, addressing inherent issues of phenotype heterogeneity and phenotype instability. Identification of treatable traits across phenotypes should improve therapeutic precision. publishedVersion
Published: 2021

16. Erratum to 'IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper' [World Allergy Organ J 13/2 (2020) 100080] (World Allergy Organization Journal (2020) 13(2), (S1939455119312360), (10.1016/j.waojou.2019.100080))

Author: Ansotegui, Ignacio J., Melioli, Giovanni, Canonica, Giorgio Walter, Caraballo, Luis, Villa, Elisa, Ebisawa, Motohiro, Passalacqua, Giovanni, Savi, Eleonora, Ebo, Didier, Gómez, R. Maximiliano, Luengo Sánchez, Olga, Oppenheimer, John J., Jensen-Jarolim, Erika, Fischer, David A., Haahtela, Tari, Antila, Martti, Bousquet, Jean J., Cardona, Victoria, Chiang, Wen Chin, Demoly, Pascal M., DuBuske, Lawrence M., Ferrer Puga, Marta, Gerth van Wijk, Roy, González Díaz, Sandra Nora, Gonzalez-Estrada, Alexei, Jares, Edgardo, Kalpaklioğlu, Ayse Füsun, Kase Tanno, Luciana, Kowalski, Marek L., Ledford, Dennis K., Monge Ortega, Olga Patricia, Morais-Almeida, Mário, Pfaar, Oliver, Poulsen, Lars K., Pawankar, Ruby, Renz, Harald E., Romano, Antonino G., Rosário Filho, Nelson A., Rosenwasser, Lanny, Sánchez Borges, Mario A., Scala, Enrico, Senna, Gian Enrico, Sisul, Juan Carlos, Tang, Mimi L.K., Yu-Hor Thong, Bernard, Valenta, Rudolf, Wood, Robert A., Zuberbier, Torsten, and Internal Medicine
Abstract: The publisher regrets we have been made aware of the below errors: 1) In Table 15, row NOVEOS chemiluminescent assay is written “utilizes 40 μL (0.04 ml) of sample per result”. The correct value would be “4 μL (0.004 ml)" of sample per result.2) In Table 16, is written “NOVEOS menu has 79 available allergens, consisting of 69 extracts and 10 molecular allergens”. It should say “NOVEOS menu continues to increase and it has 152 total allergens with 108 extracts and 44 components".3) In Table 15, row “Euroimmun”, column “Patient's serum”, is written “1000 ml”. The correct value would be “0.1 ml (-0.4 ml)”.The publisher would like to apologise for any inconvenience caused.
Published: 2021

17. ARIA (Allergic Rhinitis and its Impact on Asthma) 2019. Percorsi di cura per la rinite allergica – ITALIA

Author: Passalacqua, Giovanni, Cecchi, Lorenzo, Canonica, Giorgio Walter, Lombardi, Carlo, Ventura, Maria Teresa, Bachert, Claus, Fokkens, Wystke J., Haahtela, Tari, Klimek, Ludger, Papadopoulos, Nikos G., Pfaar, Oliver, Valiulis, Arunas, Onorato, Gabrielle L., Czarlewski, Wienczyslawa, Bedbrook, Anna, Bousquet Per Conto del Gruppo Aria-Italia, Jean, Ear, Nose and Throat, and AII - Inflammatory diseases
Subjects: animal structures, ARIA, Specific immunotherapy, Digital technology, Pharmacological therapy, Guidelines, App, Allergic rhinitis
Abstract: Allergic rhinitis and asthma represent global health problems for all age groups. ARIA (Allergic Rhinitis and its Impact on Asthma) project was initiated during a WHO workshop in 1999 In its 2010 and 2017 Revisions, ARIA has developed clinical practice guidelines for the management of allergic rhinitis and asthma co-morbidities based on GRADE (Grading of Recommendation, Assessment, Development and Evaluation). The 2019 Revision embedded real-life data into the GRADE recommendations to develop next-generation guidelines. Care pathways for allergen immunotherapy proposed a multi-sectoral approach. This paper reviews these two recent documents adding the impact of ARIA in Italy.
Published: 2021

18. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

Author: Bousquet, Jean, Pfaar, Oliver, Agache, Ioana, Bedbrook, Anna, Akdis, Cezmi A, Canonica, Giorgio Walter, Chivato, Tomas, Al-Ahmad, Mona, Rasib, A. H. Abdul, Ansotegui, Ignacio J, Bachert, Claus, Soto-Martinez, Manuel, Laune, Daniel, Casale, Tomas, Levin, Michael, Larenas-Linnemann, Désirée, Samolinski, Boleslaw, Lodrup Carlsen, Karin C, O'Mahony, Liam, Lombardi, Carlo, Riggioni, Carmen, Hossny, Elham, Barata, Luís Taborda, Lourenço, Olga, Devillier, Philippe, Mahboub, Bassam, Malling, Hans-Jørgen, Sheikh, Aziz, Manning, Patrick, Passalacqua, Giovanni, Marshall, Gailen D, Sanchez-Borges, Mario, Toppila-Salmi, Sanna, Melén, Erik, Fokkens, Wytske J, Meltzer, Eli O, Miculinic, Neven, Soto-Quiros, Manuel, Milenkovic, Branislava, Roberts, Graham, Ohta, Ken, Scichilone, Nicola, Moin, Mostafa, Odemyr, Mikaëla, Montefort, Stephen, Almeida, Mário Morais, Bom, Ana Todo, Mortz, Charlotte G, Serpa, Faradiba S, Patella, Vincenzo, Sova, Milan, Mösges, Ralph, Mullol, Joaquim, Namazova Baranova, Leyla, Tsiligianni, Ioanna, Neffen, Hugo, Bjermer, Leif, Rodriguez-Gonzales, Monica, Torres, Maria J, Okamoto, Yoshitaka, Okubo, Kimi, Pajno, Giovanni B, Baharuddin, Abdullah, Cecchi, Lorenzo, Sastre, Joaquin, Untersmayr, Eva, Pawankar, Ruby, Pham-Thi, Nhân, Plavec, Davor, Cardona, Victoria, Dokic, Dejan, Sisul, Juan Carlos, Rosario, Nelson, Rottem, Menachem, Rouadi, Philip W, Del Giacco, Stefano, Fonseca, Joao A, Schwarze, Jürgen, Scadding, Glenis K, Shamji, Mohamed H, Schmid-Grendelmeier, Peter, Niedoszytko, Marek, Valentin-Rostan, Marylin, Sofiev, Mikhail, Solé, Dirceu, Sooronbaev, Talant, Palkonen, Susanna, Urrutia-Pereira, Marilyn, Skypala, Isabel, Suppli-Ulrik, Charlotte, Bonini, Matteo, Popov, Todor A, Tomazic, Peter-Valentin, Valero, Antonio, Cepeda Sarabia, Alfonso M, Ryan, Dermot, Bosnic-Anticevich, Sinthia, Valiulis, Arunas, Durham, Stephen L, Schünemann, Holger, Kalayci, Omer, Valovirta, Erkka, Panzner, Petr, Vandenplas, Olivier, Ventura, Maria Teresa, Gotua, Maia, Vichyanond, Pakit, Chkhartishvili, Ekaterine, Wagenmann, Martin, Fontaine, Jean-François, Kull, Inger, Wallace, Dana, Recto, Marysia, Walusiak-Skorupa, Jolanta, Wang, De Yun, Hrubiško, Martin, Waserman, Susan, Ebisawa, Motohiro, Bosse, Isabelle, Grisle, Ineta, Wong, Gary Wk, Bindslev-Jensen, Carsten, Yorgancioglu, Arzu, Yusuf, Osman M, Khaitov, Musa, Zernotti, Mario, Gawlik, Radoslaw, Chu, Derek K, Irani, Carla, Zhang, Luo, Zidarn, Mihaela, Zuberbier, Torsten, Kuna, Piotr, Jutel, Marek, Guzmán, Maria Antonieta, El-Gamal, Yehia, Klimek, Ludger, Brough, Helen A, Brussino, Luisa, Calderon, Moises A, Caraballo, Luis, O'Hehir, Robyn E, Gelincik, Asli, Kvedariene, Violeta, Cirule, Ieva, Cruz, Alvaro A, Czarlewski, Wienczyslawa, Nekam, Kristof, Papadopoulos, Nikolaos G., Haahtela, Tari, Emuzyte, Regina, Gamkrelidze, Amiran, Fauquert, Jean Luc, Palomares, Oscar, Regateiro, Frederico S, Ivancevich, Juan Carlos, Gemicioglu, Bilun, Gereda, Jose E, Gerth van Wijk, Roy, Bergmann, Karl-Christian, Knol, Edward, Halken, Susanne, Heffler, Enrico, Hoffmann-Sommergruber, Karin, Martins, Pedro Carreiro, Kritikos, Vicky, Ispayeva, Zhanat, Julge, Kaja, Kaidashev, Igor, Demoly, Pascal, Kowalski, Marek, Kraxner, Helga, Ollert, Markus, Fiocchi, Alessandro, Lauerma, Antti, Lau, Susanne, Park, Hae-Sim, Gomez, R Maximiliano, Comprehensive Health Research Centre (CHRC) - pólo NMS, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), uBibliorum, Bousquet J., Pfaar O., Agache I., Bedbrook A., Akdis C.A., Canonica G.W., Chivato T., Al-Ahmad M., Abdul Latiff A.H., Ansotegui I.J., Bachert C., Baharuddin A., Bergmann K.-C., Bindslev-Jensen C., Bjermer L., Bonini M., Bosnic-Anticevich S., Bosse I., Brough H.A., Brussino L., Calderon M.A., Caraballo L., Cardona V., Carreiro-Martins P., Casale T., Cecchi L., Cepeda Sarabia A.M., Chkhartishvili E., Chu D.K., Cirule I., Cruz A.A., Czarlewski W., del Giacco S., Demoly P., Devillier P., Dokic D., Durham S.L., Ebisawa M., El-Gamal✝ Y., Emuzyte R., Gamkrelidze A., Fauquert J.L., Fiocchi A., Fokkens W.J., Fonseca J.A., Fontaine J.-F., Gawlik R., Gelincik A., Gemicioglu B., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gotua M., Grisle I., Guzman M.-A., Haahtela T., Halken S., Heffler E., Hoffmann-Sommergruber K., Hossny E., Hrubisko M., Irani C., Ivancevich J.C., Ispayeva Z., Julge K., Kaidashev I., Kalayci O., Khaitov M., Klimek L., Knol E., Kowalski M.L., Kraxner H., Kull I., Kuna P., Kvedariene V., Kritikos V., Lauerma A., Lau S., Laune D., Levin M., Larenas-Linnemann D.E., Lodrup Carlsen K.C., Lombardi C., Lourenco O.M., Mahboub B., Malling H.-J., Manning P., Marshall G.D., Melen E., Meltzer E.O., Miculinic N., Milenkovic B., Moin M., Montefort S., Morais-Almeida M., Mortz C.G., Mosges R., Mullol J., Namazova Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Ollert M., O'Mahony L., Ohta K., Okamoto Y., Okubo K., Pajno G.B., Palomares O., Palkonen S., Panzner P., G Papadopoulos N., Park H.-S., Passalacqua G., Patella V., Pawankar R., Pham-Thi N., Plavec D., Popov T.A., Recto M., Regateiro F.S., Riggioni C., Roberts G., Rodriguez-Gonzales M., Rosario N., Rottem M., Rouadi P.W., Ryan D., Samolinski B., Sanchez-Borges✝ M., Serpa F.S., Sastre J., Scadding G.K., Shamji M.H., Schmid-Grendelmeier P., Schunemann H.J., Sheikh A., Scichilone N., Sisul J.C., Sofiev M., Sole D., Sooronbaev T., Soto-Martinez M., Soto-Quiros M., Sova M., Schwarze J., Skypala I., Suppli-Ulrik C., Taborda-Barata L., Todo-Bom A., Torres M.J., Valentin-Rostan M., Tomazic P.-V., Valero A., Toppila-Salmi S., Tsiligianni I., Untersmayr E., Urrutia-Pereira M., Valiulis A., Valovirta E., Vandenplas O., Ventura M.T., Vichyanond P., Wagenmann M., Wallace D., Walusiak-Skorupa J., Wang D.Y., Waserman S., Wong G.W.K., Yorgancioglu A., Yusuf O.M., Zernotti M., Zhang L., Zidarn M., Zuberbier T., Jutel M., HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, Department of Pathology, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Philipps Universität Marburg = Philipps University of Marburg, Transilvania University of Brasov, Universität Zürich [Zürich] = University of Zurich (UZH), Humanitas University [Milan] (Hunimed), Universidad San Pablo CEU, Kuwait University, Al-Rashed Allergy Center [Kuwait City], Pantai Hospital [Kuala Lumpur], Hospital Quirónsalud Bizkaia [Bilbao], Ghent University Hospital, Karolinska Institutet [Stockholm], Karolinska University Hospital [Stockholm], Sun Yat-Sen University [Guangzhou] (SYSU), Universiti Sains Malaysia (USM), Humboldt University Of Berlin, Berlin Institute of Health (BIH), Odense University Hospital (OUH), Skane University Hospital [Lund], Fondazione Policlinico Universitario Agostino Gemelli IRCCS, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Woolcock Institute of Medical Research [Sydney], The University of Sydney, Guy's and St Thomas' Hospital [London], King‘s College London, Università degli studi di Torino = University of Turin (UNITO), University of Cartagena, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), University of South Florida [Tampa] (USF), Azienda Usl Toscana centro [Firenze], Universidad Simon Bolivar (USB), David Tvildiani Medical University (DTMU), McMaster University [Hamilton, Ontario], Children's Clinical University Hospital [Riga, Latvia] (CCUH), Universidade Federal da Bahia (UFBA), Università degli Studi di Cagliari = University of Cagliari (UniCa), Epidemiology of Allergic and Respiratory Diseases Department [iPlesp] (EPAR), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Foch [Suresnes], Sagamihara National Hospital [Kanagawa, Japan], Université Ain Shams, Vilnius University [Vilnius], CHU Clermont-Ferrand, IRCCS Ospedale Pediatrico Bambino Gesù [Roma], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Universidade do Porto = University of Porto, Silesian Medical University, Katowice, Poland, Cerrahpasa Faculty of Medicine, Istanbul University, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Universidad de Chile = University of Chile [Santiago] (UCHILE), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Medizinische Universität Wien = Medical University of Vienna, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Tartu University Hospital [Tartu, Estonia], Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Hacettepe University = Hacettepe Üniversitesi, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Siriraj Hospital, Mahidol University, Mahidol University [Bangkok], Nova Southeastern University (NSU), Nofer Institute of Occupational Medicine (NIOM), National University of Singapore (NUS), Yong Loo Lin School of Medicine [Singapore], The Chinese University of Hong Kong [Hong Kong], Manisa Celal Bayar University, Universidad Nacional de Villa María, Universidad Católica de Córdoba, Beijing Tongren Hospital, Herrada, Anthony, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (MGD) Service de pneumologie
Subjects: Pulmonary and Respiratory Medicine, precision medicine, education, Immunology, Review, Settore MED/10 - Malattie Dell'Apparato Respiratorio, immune system diseases, HDE ALER, allergic rhinitis, asthma, immunotherapy, Medicine and Health Sciences, Immunology and Allergy, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, ComputingMilieux_MISCELLANEOUS, Rhinitis, RC581-607, respiratory tract diseases, 3121 General medicine, internal medicine and other clinical medicine, Immunologic diseases. Allergy, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology, allergic rhinitis, asthma, immunotherapy, precision medicine
Abstract: Funding Information: BSreports personal fees from Allergopharma, during the conduct of the study; grants from National Health Programm, grant, personal fees from Polpharma, ASTRA, personal fees from Mylan, Adamed, patient ombudsman, national Centre for Research and Development, Polish Allergology Society. Funding Information: NGP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. Funding Information: CA reports grants from Allergopharma, grants from Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Research and Education, European Commission's Horison's 2020 Framework Programme, Cure, Novartis Research Institutes, Astra Zeneca, scibase, advisory role in Sanofi/Regeneron, grants from Glakso Smith‐Kline, advisory role in scibase. Funding Information: MJTreports grants from European Commission, SEAIC, ISCIII, personal fees from Diater laboratory, Leti laboratory, Aimmune Therapeutics. Funding Information: LK reports grants and personal fees from Allergopharma, MEDA/Mylan, LETI Pharma, Sanofi, grants from Stallergenes, Quintiles, ASIT biotech, grants from ALK Abelló, Lofarma, AstraZeneca, GSK, Inmunotk, personal fees from Allergy Therapeut., HAL Allergie, Cassella med; and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, EAACI. Funding Information: DPreports grants and personal fees from GlaxoSmithKline, personal fees from Menarini, Pliva, Belupo, AbbVie, Novartis, MSD, Chiesi, Revenio, personal fees and non‐financial support from Boehringer Ingelheim, non‐financial support from Philips. Funding Information: OP reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., Glaxo Smith Kline, grants from Biomay, Circassia, Pohl‐Boskamp, Inmunotek S.L., personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS. Copyright: Copyright 2021 Elsevier B.V., All rights reserved. publishersversion published
Published: 2021

19. Eosinophilic and Noneosinophilic Asthma An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

Author: Heaney, Liam G. de Llano, Luis Perez Al-Ahmad, Mona Backer, Vibeke Busby, John Canonica, Giorgio Walter Christoff, George C. Cosio, Borja G. FitzGerald, J. Mark Heffler, Enrico Iwanaga, Takashi Jackson, David J. Menzies-Gow, Andrew N. Papadopoulos, Nikolaos G. Papaioannou, I, Andriana and Pfeffer, Paul E. Popov, Todor A. Porsbjerg, Celeste M. Rhee, Chin Kook Sadatsafavi, Mohsen Tohda, Yuji Wang, Eileen and Wechsler, Michael E. Alacqua, Marianna Altraja, Alan and Bjermer, Leif Bjornsdottir, Unnur S. Bourdin, Arnaud and Brusselle, Guy G. Buhl, Roland Costello, Richard W. Hew, Mark Koh, Mariko Siyue Lehmann, Sverre Lehtimaki, Lauri and Peters, Matthew Taille, Camille Taube, Christian Tran, Trung N. Zangrilli, James Bulathsinhala, Lakmini Carter, Victoria A. Chaudhry, Isha Eleangovan, Neva Hosseini, Naeimeh and Kerkhof, Marjan Murray, Ruth B. Price, Chris A. Price, David B.
Abstract: BACKGROUND: Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe asthma cohorts. RESEARCH QUESTION: What is the prevalence of eosinophilic and noneosinophilic phenotypes in the population with severe asthma, and can these phenotypes be differentiated by clinical and biomarker variables? STUDY DESIGN AND METHODS: This was an historical registry study. Adult patients with severe asthma and available blood eosinophil count (BEC) from 11 countries enrolled in the International Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized according to likelihood of eosinophilic phenotype using a predefined gradient eosinophilic algorithm based on highest BEC, long-term oral corticosteroid use, elevated fractional exhaled nitric oxide, nasal polyps, and adult-onset asthma. Demographic and clinical characteristics were defined at baseline (ie, 1 year before or closest to date of BEC). RESULTS: One thousand seven hundred sixteen patients with prospective data were included; 83.8% were identified as most likely (grade 3), 8.3% were identified as likely (grade 2), and 6.3% identified as least likely (grade 1) to have an eosinophilic phenotype, and 1.6% of patients showed a noneosinophilic phenotype (grade 0). Eosinophilic phenotype patients (ie, grades 2 or 3) showed later asthma onset (29.1 years vs 6.7 years; P
Published: 2021

20. EAACI Biologicals Guidelines-Recommendations for severe asthma

Author: Agache, Ioana, Akdis, Cezmi A, Akdis, Mubeccel, Canonica, Giorgio Walter, Casale, Thomas, et al, University of Zurich, and Agache, Ioana
Subjects: 2403 Immunology, 10183 Swiss Institute of Allergy and Asthma Research, 2723 Immunology and Allergy, 610 Medicine & health
Published: 2021

21. COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

Author: Heffler, Enrico, Detoraki, Aikaterini, Contoli, Marco, Papi, Alberto, Paoletti, Giovanni, Malipiero, Giacomo, Brussino, Luisa, Crimi, Claudia, Morrone, Daniela, Padovani, Marianna, Guida, Giuseppe, Gerli, Alberto Giovanni, Centanni, Stefano, Senna, Gianenrico, Paggiaro, Pierluigi, Blasi, Francesco, Canonica, Giorgio Walter, SANI Working Group, Bonavia, M, Bucca, C, Caiaffa, Mf, Calabrese, C, Camiciottoli, G, Caruso, C, Conte, Me, Corsico, Ag, Cosmi, L, Costantino, Mt, Crimi, N, D’Alò, S, D’Amato, M, Del Giacco, S, Farsi, A, Favero, E, Foschino, Bmp, Guarnieri, G, Lo Cicero, S, Lombardi, C, Macchia, L, Mazza, F, Menzella, F, Milanese, M, Montuschi, P, Montagni, M, Nucera, E, Parente, R, Passalacqua, G, Patella, V, Pelaia, G, Pini, L, Puggioni, F, Ricciardi, L, Ricciardolo, Flm, Richeldi, L, Ridolo, E, Rolla, G, Santus, P, Scichilone, N, Solidoro, P, Spadaro, G, Vianello, A, Viviano, V, Yacoub, Mr, Zappa, Mc, Heffler E., Detoraki A., Contoli M., Papi A., Paoletti G., Malipiero G., Brussino L., Crimi C., Morrone D., Padovani M., Guida G., Gerli A.G., Centanni S., Senna G., Paggiaro P., Blasi F., Canonica G.W., Bonavia M., Bucca C., Caiaffa M.F., Calabrese C., Camiciottoli G., Caruso C., Conte M.E., Corsico A.G., Cosmi L., Costantino M.T., Crimi N., D'Alo S., D'Amato M., Del Giacco S., Farsi A., Favero E., Foschino B.M.P., Guarnieri G., Cicero S.L., Lombardi C., Macchia L., Mazza F., Menzella F., Milanese M., Montuschi P., Montagni M., Nucera E., Parente R., Passalacqua G., Patella V., Pelaia G., Pini L., Puggioni F., Ricciardi L., Ricciardolo F.L.M., Richeldi L., Ridolo E., Rolla G., Santus P., Scichilone N., Solidoro P., Spadaro G., Vianello A., Viviano V., Yacoub M.R., and Zappa M.C.
Subjects: severe asthma, medicine.medical_specialty, 2019-20 coronavirus outbreak, COVID-19, Severe Asthma Network in Italy, inflammation, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Severe asthma, Population, Immunology, MEDLINE, Omalizumab, Settore MED/10 - Malattie Dell'Apparato Respiratorio, NO, Internal medicine, Diabetes mellitus, Severity of illness, medicine, Immunology and Allergy, Risk factor, Letters to the Editor, education, Letter to the Editor, Asthma, education.field_of_study, business.industry, Incidence (epidemiology), Mortality rate, COVID-19, medicine.disease, Comorbidity, Severe Asthma Network in Italy, inflammation, Cohort, business, Mepolizumab, medicine.drug
Abstract: To the Editor Since the end of February 2020 Italy, first non- Asian Country, has reported an ever increasing number of COronaVIrus Disease 19 (COVID-19) patients, which has reached over 200,000 confirmed Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infected subjects and resulted in more than 34000 deaths (data updated to June 19th, 20201).Patients with asthma are potentially more severely affected by by SARS-CoV-2 infection 2 and it is well established that respiratory viral infections are associated with severe adverse outcomes in patients with asthma, including increased risk of asthma exacerbation episodes 3. Nonetheless, according to the epidemiological studies published so far, chronic pulmonary diseases are not amongst the most common clinical conditions in COVID-19 patients4About 5-10% of entire asthma population, are severe asthmatics5 and one would expect increased vulnerability to SARS-CoV-2 infection, but no data is so fare available ti confirm this hypothesis.We investigated the incidence of COVID-19, describing its clinical course, in the population of the Severe Asthma Network in Italy (SANI), one of the largest registry for severe asthma worldwide6, and in an additional Center (Azienda Ospedaliero Univeristaria di Ferrara, Ferrara, Italy). All centers, have been contacted and inquired to report confirmed (i.e. patients with positive test result for the virus SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens) or highly suspect cases of COVID-19 (i.e. patients with symptoms, laboratory findings and lung imaging typical of COVID-19 but without access to nasopharyngeal or oropharyngeal swab specimens because of clinical contingencies/emergency) among their cohorts of severe asthma. Demographic and clinical data of the entire cohort of severe asthmatics enrolled in the study and all reported cases of confirmed or suspect cases of COVID-19, have been obtained from the registry platform and collected from the additional Center. Additional data about COVID-19 symptoms, treatment and clinical course have been collected for all cases reported.Ethical issues and statistical analysis are reported in the online supplementary material.Twenty-six (1.73%) out of 1504 severe asthmatics had confirmed (11 out of 26) or highly suspect COVID-19 (15 out 26); eighteen (69.2%) were females and mean age was 56.2 ± 10 years. The geographical distribution of COVID-19 cases is presented in Figure 1.Nine (34.6%) infected patients experienced worsening of asthma during the COVID-19 symptomatic period; four of them needed a short course of oral corticosteroids for controlling asthma exacerbation symptoms.The most frequent COVID-19 symptoms reported were fever (100% of patients), malaise (84.6%), cough (80.8%), dyspnea (80.8%), headache (42.3%) and loss of smell (42.3%). Four patients (15.3%) have been hospitalized, one of which in intensive care unit; among hospitalized patients, two (7.7%) died for COVID-19 interstitial pneumonia. No deaths have been reported among the non-hospitalized patients.Severe asthmatics affected by COVID-19, had a significantly higher prevalence of non-insulin-dependent diabetes mellitus (NIDDM) compared to non-infected severe asthma patients (15.4% vs 3.8%, p=0.002; odds ratio: 4.7). No difference was found in other comorbidities (including rhinitis, chronic rhinosinusitis with or without nasal polyps, bronchiectasis, obesity, gastroesophageal reflux, arterial hypertension, cardiovascular diseases).Twenty-one patients with COVID-19 were on biological treatments: 15 (71%) were on anti-IL-5 or anti-IL5R agents (Mepolizumab n= 13; Benralizumab n=2 - counting for the 2.9% of all severe asthmatics treated with anti-IL5 in our study population) and 6 (29%) were on anti IgE (Omalizumab - 1.3% of all severe asthmatics treated with omalizumab in our study population).Table I summarizes demographic and clinical characteristics of the 26 COVID-19 patients.In conclusion, in our large cohort of severe asthmatics, COVID-19 was infrequent, not supporting the concept of asthma as a particularly susceptible condition to SARS-COV2 infection 2. This is in line with the first published large epidemiological data on COVID-19 patients, in which asthma is under-reported as comorbidity4. The COVID-19 related mortality rate in our cohort of patients was 7.7%, lower than the COVID-19 mortality rate in the general population (14.5% in Italy 1). These findings suggest that severe asthmatics are not at high risk of the SARS-CoV-2 infection and of severe forms of COVID-19. There are potentially different reasons for this. Self-containment is the first, because of the awareness of virus infections acting as a trigger for exacerbations, and therefore they could have acted with greater caution, scrupulously respecting social distancing, lockdown and hygiene rules of prevention, and being more careful in regularly taking asthma medications.Another possible explanation stands in the intrinsic features of type-2 inflammation, that characterizes a great proportion of severe asthmatics. Respiratory allergies and controlled allergen exposures are associated with significant reduction in angiotensin-converting enzyme 2 (ACE2) expression 7, the cellular receptor for SARS-CoV-2. Interestingly, ACE2 and Transmembrane Serine Protease 2 (TMPRSS2) (another protein mediating SARS-CoV-2 cell entry) have been found highly expressed in asthmatics with concomitant NIDDM8, the only comorbidity that was more frequent reported in our COVID-19 severe asthmatics.The third possible explanation refers to the possibility that inhaled corticosteroids (ICS) might prevent or mitigate the development of Coronaviruses infections. By definition, patients with severe asthma are treated with high doses of ICS 5 and this may have had a protective effect for SARS-CoV-2 infection.Noteworthy, among the patients of our case-series of severe asthmatics with COVID-19, the proportion of those treated anti-IL5 biologics was higher (71%) compared to the number of patients treated with anti-IgE (29%). Although the number of cases is too small to draw any conclusion, it is tempting to speculate that different biological treatments can have specific and different impact on antiviral immune response. In addition we may speculate of the consequence of blood eosinophils reduction: eosinopenia has been reported in 52-90% of COVID-19 patients worldwide and it has been suggested as a risk factor for more severe COVID-19 9.In conclusion, in our large cohort of severe asthmatics only a small minority experienced symptoms consistent with COVID-19, and these patients had peculiar clinical features including high prevalence of NIDDM as comorbidity. Further real-life registry-based studies are needed to confirm our findings and to extend the evidence that severe asthmatics are at low risk of developing COVID-19.
Published: 2021

22. Is diet partly responsible for differences in COVID-19 death rates between and within countries? : protocol for a systematic review

Author: Bousquet, Jean, Antò i Boquè, Josep M., Laccarino, Guido, Czarlewski, Wienczyslawa, Haahtela, Tari, Anto, Aram, Akdis, Cezmi A., Blain, Hubert, Canonica, Giorgio Walter, Kramer Vrščaj, Karmen, Košnik, Mitja, Koren, Anja, Kopač, Peter, Jošt, Maja, Kreft, Samo, Jenko, Klemen, Madjar, Bojan, Plavec, Davor, Soklič, Tanja, Urbančič, Jure, and Zidarn, Mihaela
Subjects: angiotenzin, udc:616.9:66.094.3.097.8, angiotensin-converting enzyme, antioxidant, antioksidanti, primerjave bolezni Covid-19, food, covid 19, coronavirus, diet, hrana
Abstract: Reported COVID-19 deaths in Germany are relatively low as compared to many European countries. Among the several explanations proposed, an early and large testing of the population was put forward. Most current debates on COVID-19 focus on the differences among countries, but little attention has been given to regional differences and diet. The low-death rate European countries (e.g. Austria, Baltic States, Czech Republic, Finland, Norway, Poland, Slovakia) have used different quarantine and/or confinement times and methods and none have performed as many early tests as Germany. Among other factors that may be significant are the dietary habits. It seems that some foods largely used in these countries may reduce angiotensin-converting enzyme activity or are anti-oxidants. Among the many possible areas of research, it might be important to understand diet and angiotensin-converting enzyme-2 (ACE2) levels in populations with different COVID-19 death rates since dietary interventions may be of great benefit.
Published: 2020

23. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Author: Agache, Ioana, Beltran, Jessica, Akdis, Cezmi, Akdis, Mubeccel, Canelo‐Aybar, Carlos, Canonica, Giorgio Walter, Casale, Thomas, Chivato, Tomas, Corren, Jonathan, et al, University of Zurich, and Agache, Ioana
Subjects: 2403 Immunology, 10183 Swiss Institute of Allergy and Asthma Research, Immunology, 2723 Immunology and Allergy, Immunology and Allergy, 610 Medicine & health
Published: 2020

24. Correction to 'ARIA guideline 2019: treatment of allergic rhinitis in the German health system' (Allergo Journal International, (2019), 28, 7, (255-276), 10.1007/s40629-019-00110-9)

Author: Klimek, Ludger, Bachert, Claus, Pfaar, Oliver, Becker, Sven, Bieber, Thomas, Brehler, Randolf, Buhl, Roland, Casper, Ingrid, Chaker, Adam, Czech, Wolfgang, Fischer, J. rg, Fuchs, Thomas, Gerstlauer, Michael, Hörmann, Karl, Jakob, Thilo, Jung, Kirsten, Kopp, Matthias V., Mahler, Vera, Merk, Hans, Mülleneisen, Norbert, Nemat, Katja, Rabe, Uta, Ring, Johannes, Saloga, Joachim, Schlenter, Wolfgang, Schmidt-Weber, Carsten, Seyfarth, Holger, Sperl, Annette, Spindler, Thomas, Staubach, Petra, Strieth, Sebastian, Treudler, Regina, Vogelberg, Christian, Wallrafen, Andrea, Wehrmann, Wolfgang, Wrede, Holger, Zuberbier, Torsten, Bedbrook, Anna, Canonica, Giorgio W., Cardona, Victoria, Casale, Thomas B., Czarlewski, Wienczylawa, Fokkens, Wytske J., Hamelmann, Eckard, Hellings, Peter W., Jutel, Marek, Larenas-Linnemann, D. sirée, Mullol, Joaquim, Papadopoulos, Nikolaos G., Toppila-Salmi, Sanna, Werfel, Thomas, Bousquet, Jean, Ear, Nose and Throat, and AII - Inflammatory diseases
Abstract: Correction to: Allergo J Int 2019 https://doi.org/10.1007/s40629-019-00110-9 Affiliation and disclaimer have been misrepresented and are hereby corrected: Vera Mahler: Affiliation: Med. Faculty, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Germany. Disclaimer: The views expressed in this.
Published: 2020

25. Additional file 1 of International severe asthma registry (ISAR): protocol for a global registry

Author: J. Mark FitzGerald, Tran, Trung N., Alacqua, Marianna, Altraja, Alan, Backer, Vibeke, Bjermer, Leif, Bjornsdottir, Unnur, Bourdin, Arnaud, Brusselle, Guy, Lakmini Bulathsinhala, Busby, John, Canonica, Giorgio W., Carter, Victoria, Isha Chaudhry, Cho, You Sook, Christoff, George, Cosio, Borja G., Costello, Richard W., Eleangovan, Neva, Gibson, Peter G., Heaney, Liam G., Heffler, Enrico, Hew, Mark, Naeimeh Hosseini, Iwanaga, Takashi, Jackson, David J., Jones, Rupert, Koh, Mariko S., Le, Thao, Lehtimäki, Lauri, Ludviksdottir, Dora, Zee, Anke H. Maitland-Van Der, Menzies-Gow, Andrew, Murray, Ruth B., Papadopoulos, Nikolaos G., Perez-De-Llano, Luis, Peters, Matthew, Pfeffer, Paul E., Popov, Todor A., Porsbjerg, Celeste M., Price, Chris A., Rhee, Chin K., Sadatsafavi, Mohsen, Tohda, Yuji, Wang, Eileen, Wechsler, Michael E., Zangrilli, James, and Price, David B.
Subjects: surgical procedures, operative, education, macromolecular substances, digestive system, digestive system diseases
Abstract: Additional file 1: Appendix. International Severe Asthma Registry study group.
Published: 2020
Full Text: View/download PDF

26. International expert consensus on the management of allergic rhinitis (AR) aggravated by air pollutants: Impact of air pollution on patients with AR: Current knowledge and future strategies

Author: Naclerio, Robert N., Ansotegui, Ignacio Javier, Bousquet, Jean J., Canonica, Giorgio Walter, D'Amato, Gennaro, Rosario, Nélson Augusto, Pawankar, Ruby U., Peden, David Blaine, Bergmann, Karl Christian, Bielory, Leonard, Caraballo, Luis R., Cecchi, Lorenzo, Cepeda, S. Alfonso M., Chong Neto, Herberto José, Galán, C., Gonzalez Diaz, Sandra Nora, Idriss, Samar A., Popov, T. A., Ramon, Germán Darío, Ridolo, Erminia, Rottem, Menachem, Songnuan, Wisuwat, Rouadi, Philip W., Virologie et Immunologie Moléculaires (VIM (UR 0892)), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Subjects: Oxidative stress, [SDV]Life Sciences [q-bio], Air pollution, Climate change, Antioxidant enzymes, Indoor air quality, Occupational rhinitis, Allergic rhinitis, Air pollutants
Abstract: International audience; Allergic rhinitis affects the quality of life of millions of people worldwide. Air pollution not only causes morbidity, but nearly 3 million people per year die from unhealthy indoor air exposure. Furthermore, allergic rhinitis and air pollution interact. This report summarizes the discussion of an International Expert Consensus on the management of allergic rhinitis aggravated by air pollution. The report begins with a review of indoor and outdoor air pollutants followed by epidemiologic evidence showing the impact of air pollution and climate change on the upper airway and allergic rhinitis. Mechanisms, particularly oxidative stress, potentially explaining the interactions between air pollution and allergic rhinitis are discussed. Treatment for the management of allergic rhinitis aggravated by air pollution primarily involves treating allergic rhinitis by guidelines and reducing exposure to pollutants. Fexofenadine a non-sedating oral antihistamine improves AR symptoms aggravated by air pollution. However, more efficacy studies on other pharmacological therapy of coexisting AR and air pollution are currently lacking.
Published: 2020

27. Additional file 3 of International severe asthma registry (ISAR): protocol for a global registry

Author: J. Mark FitzGerald, Tran, Trung N., Alacqua, Marianna, Altraja, Alan, Backer, Vibeke, Bjermer, Leif, Bjornsdottir, Unnur, Bourdin, Arnaud, Brusselle, Guy, Lakmini Bulathsinhala, Busby, John, Canonica, Giorgio W., Carter, Victoria, Isha Chaudhry, Cho, You Sook, Christoff, George, Cosio, Borja G., Costello, Richard W., Eleangovan, Neva, Gibson, Peter G., Heaney, Liam G., Heffler, Enrico, Hew, Mark, Naeimeh Hosseini, Iwanaga, Takashi, Jackson, David J., Jones, Rupert, Koh, Mariko S., Le, Thao, Lehtimäki, Lauri, Ludviksdottir, Dora, Zee, Anke H. Maitland-Van Der, Menzies-Gow, Andrew, Murray, Ruth B., Papadopoulos, Nikolaos G., Perez-De-Llano, Luis, Peters, Matthew, Pfeffer, Paul E., Popov, Todor A., Porsbjerg, Celeste M., Price, Chris A., Rhee, Chin K., Sadatsafavi, Mohsen, Tohda, Yuji, Wang, Eileen, Wechsler, Michael E., Zangrilli, James, and Price, David B.
Subjects: nervous system, education, macromolecular substances, health care economics and organizations, respiratory tract diseases
Abstract: Additional file 3: Table S2. International Severe Asthma Registry bolt-on variables.
Published: 2020
Full Text: View/download PDF

28. Additional file 3 of Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis

Author: Heffler, Enrico, Saccheri, Fabiana, Bartezaghi, Marta, and Canonica, Giorgio Walter
Abstract: Additional file 3: Figure S3. Efficacy comparison of outcome parameters at baseline and 12 months after omalizumab treatment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared with severe asthma (no chronic rhinosinusitis or nasal polyps). (A) Mean Asthma Control Questionnaire scores, and the change from baseline in ACQ score; (B) Median percent predicted forced expiratory volume in 1 s (FEV1), and change from baseline in percent predicted FEV1; (C) Median number of annual exacerbations in the year prior to initiating omalizumab treatment (baseline) and during 12 months’ treatment with omalizumab, and change from baseline. The p-values within cohorts were calculated using a signed rank test and p-values for comparisons between cohorts were calculated using an ANCOVA model on ranks.
Published: 2020
Full Text: View/download PDF

29. Additional file 1 of Physicians’ prescribing behaviour and clinical practice patterns for allergic rhinitis management in Italy

Author: Passalacqua, Giovanni, Musarra, Antonino, Senna, Gianenrico, Bousquet, Jean, Ferrara, Carmen, Lonati, Caterina, and Canonica, Giorgio Walter
Abstract: Additional file 1. Supplementary methods and results.
Published: 2020
Full Text: View/download PDF

30. Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?

Author: Heffler, Enrico, Detoraki, Aikaterini, Contoli, Marco, Papi, Alberto, Paoletti, Giovanni, Malipiero, Giacomo, Brussino, Luisa, Crimi, Claudia, Morrone, Daniela, Padovani, Marianna, Guida, Giuseppe, Gerli, Alberto Giovanni, Centanni, Stefano, Senna, Gianenrico, Paggiaro, Pierluigi, Blasi, Francesco, Canonica, Giorgio Walter, SANI Working Group, Bonavia, M., Bucca, C., Caiaffa, M. F., Calabrese, C., Camiciottoli, G., Caruso, C., Conte, M. E., Corsico, A. G., Cosmi, L., Costantino, M. T., Crimi, N., D’Alò, S., D’Amato, M., Del Giacco, S., Farsi, A., Favero, E., Foschino, B. M. P., Guarnieri, G., Lo Cicero, S., Lombardi, C., Macchia, L., Mazza, F., Menzella, F., Milanese, M., Montuschi, P., Montagni, M., Nucera, E., Parente, R., Passalacqua, G., Patella, V., Pelaia, G., Pini, L., Puggioni, F., Ricciardi, L., Ricciardolo, F. L. M., Richeldi, L., Ridolo, E., Rolla, G., Santus, P., Scichilone, N., Solidoro, P., Spadaro, G., Vianello, A., Viviano, V., Yacoub, M. R., Zappa, M. C., Heffler E., Detoraki A., Contoli M., Papi A., Paoletti G., Malipiero G., Brussino L., Crimi C., Morrone D., Padovani M., Guida G., Gerli A.G., Centanni S., Senna G., Paggiaro P., Blasi F., Canonica G.W., Bonavia M., Bucca C., Caiaffa M.F., Calabrese C., Camiciottoli G., Caruso C., Conte M.E., Corsico A.G., Cosmi L., Costantino M.T., Crimi N., D'Alo S., D'Amato M., Del Giacco S., Farsi A., Favero E., Foschino B.M.P., Guarnieri G., Lo Cicero S., Lombardi C., Macchia L., Mazza F., Menzella F., Milanese M., Montuschi P., Montagni M., Nucera E., Parente R., Passalacqua G., Patella V., Pelaia G., Pini L., Puggioni F., Ricciardi L., Ricciardolo F.L.M., Richeldi L., Ridolo E., Rollav G., Santus P., Scichilone N., Solidoro P., Spadaro G., Vianello A., Viviano V., Yacoub M.R., and Zappa M.C.
Subjects: severe asthma, 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Severe asthma, Immunology, Comorbidity, Settore MED/10 - Malattie Dell'Apparato Respiratorio, COVID-19, severe asthma, COPD, NO, Humans, SARS-CoV-2, Asthma, COVID-19, Internal medicine, Correspondence, medicine, COPD, Immunology and Allergy, COVID, business.industry, asthma, medicine.disease, Italy, business
Published: 2020

31. Additional file 1 of Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis

Author: Heffler, Enrico, Saccheri, Fabiana, Bartezaghi, Marta, and Canonica, Giorgio Walter
Abstract: Additional file 1: Figure S1. Efficacy comparison of outcome parameters at baseline and 12 months after omalizumab treatment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared with chronic sinusitis/rhinosinusutis without (CRSsNP). (A) Mean Asthma Control Questionnaire scores, and the change from baseline in ACQ score; (B) Median percent predicted forced expiratory volume in 1 s (FEV1), and change from baseline in percent predicted FEV1; (C) Median number of annual exacerbations in the year prior to initiating omalizumab treatment (baseline) and during 12 months’ treatment with omalizumab, and change from baseline. The p-values within cohorts were calculated using a signed rank test and p-values for comparisons between cohorts were calculated using an ANCOVA model on ranks.
Published: 2020
Full Text: View/download PDF

32. Additional file 4 of International severe asthma registry (ISAR): protocol for a global registry

Author: J. Mark FitzGerald, Tran, Trung N., Alacqua, Marianna, Altraja, Alan, Backer, Vibeke, Bjermer, Leif, Bjornsdottir, Unnur, Bourdin, Arnaud, Brusselle, Guy, Lakmini Bulathsinhala, Busby, John, Canonica, Giorgio W., Carter, Victoria, Isha Chaudhry, Cho, You Sook, Christoff, George, Cosio, Borja G., Costello, Richard W., Eleangovan, Neva, Gibson, Peter G., Heaney, Liam G., Heffler, Enrico, Hew, Mark, Naeimeh Hosseini, Iwanaga, Takashi, Jackson, David J., Jones, Rupert, Koh, Mariko S., Le, Thao, Lehtimäki, Lauri, Ludviksdottir, Dora, Zee, Anke H. Maitland-Van Der, Menzies-Gow, Andrew, Murray, Ruth B., Papadopoulos, Nikolaos G., Perez-De-Llano, Luis, Peters, Matthew, Pfeffer, Paul E., Popov, Todor A., Porsbjerg, Celeste M., Price, Chris A., Rhee, Chin K., Sadatsafavi, Mohsen, Tohda, Yuji, Wang, Eileen, Wechsler, Michael E., Zangrilli, James, and Price, David B.
Subjects: education, macromolecular substances, health care economics and organizations, respiratory tract diseases
Abstract: Additional file 4: Table S3. International Severe Asthma Registry optional additional research variables.
Published: 2020
Full Text: View/download PDF

33. Additional file 2 of International severe asthma registry (ISAR): protocol for a global registry

Author: J. Mark FitzGerald, Tran, Trung N., Alacqua, Marianna, Altraja, Alan, Backer, Vibeke, Bjermer, Leif, Bjornsdottir, Unnur, Bourdin, Arnaud, Brusselle, Guy, Lakmini Bulathsinhala, Busby, John, Canonica, Giorgio W., Carter, Victoria, Isha Chaudhry, Cho, You Sook, Christoff, George, Cosio, Borja G., Costello, Richard W., Eleangovan, Neva, Gibson, Peter G., Heaney, Liam G., Heffler, Enrico, Hew, Mark, Naeimeh Hosseini, Iwanaga, Takashi, Jackson, David J., Jones, Rupert, Koh, Mariko S., Le, Thao, Lehtimäki, Lauri, Ludviksdottir, Dora, Zee, Anke H. Maitland-Van Der, Menzies-Gow, Andrew, Murray, Ruth B., Papadopoulos, Nikolaos G., Perez-De-Llano, Luis, Peters, Matthew, Pfeffer, Paul E., Popov, Todor A., Porsbjerg, Celeste M., Price, Chris A., Rhee, Chin K., Sadatsafavi, Mohsen, Tohda, Yuji, Wang, Eileen, Wechsler, Michael E., Zangrilli, James, and Price, David B.
Abstract: Additional file 2: Table S1. Full list of ISAR 95 core variables.
Published: 2020
Full Text: View/download PDF

34. Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study

Author: Liccardi, G., Calzetta, L., Baldi, G., Berra, A., Billeri, L., Caminati, M., Capano, P., Carpentieri, E., Ciccarelli, A., Crivellaro, M. A., Cutajar, M., D'Amato, M., Folletti, I., Gani, F., Gargano, D., Giannattasio, D., Giovannini, M., Lombardi, C., Schiavo, M. Lo, Madonna, F., Maniscalco, M., Meriggi, A., Micucci, C., Milanese, M., Montera, C., Paolocci, G., Parente, R., Pedicini, A., Pio, R., Puggioni, F., Russo, M., Salzillo, A., Scavalli, P., Scichilone, N., Sposato, B., Stanziola, A., Steinhilber, G., Vatrella, A., Rogliani, P., Passalacqua, G., Baiardini, Ilaria, Bucca, Caterina, Canonica, Giorgio Walter, Costantino, Maria Teresa, Giacco, Stefano Del, Heffler, Enrico, Grutta, Stefania La, Patella, Vincenzo, Ridolo, Erminia, Rolla, Giovanni, Rossi, Oliviero, Savi, Eleonora, Senna, Gianenrico, Tesi, Carlo Filippo, Viegi, Giovanni, Liccardi, G., Calzetta, L., Baldi, G., Berra, A., Billeri, L., Caminati, M., Capano, P., Carpentieri, E., Ciccarelli, A., Crivellaro, M.A., Cutajar, M., D'Amato, M., Folletti, I., Gani, F., Gargano, D., Giannattasio, D., Giovannini, M., Lombardi, C., Schiavo, M.Lo, Madonna, F., Maniscalco, M., Meriggi, A., Micucci, C., Milanese, M., Montera, C., Paolocci, G., Parente, R., Pedicini, A., Pio, R., Puggioni, F., Russo, M., Salzillo, A., Scavalli, P., Scichilone, N., Sposato, B., Stanziola, A., Steinhilber, G., Vatrella, A., Rogliani, P., Passalacqua, G., Baiardini, Ilaria, Bucca, Caterina, Canonica, Giorgio Walter, Costantino, Maria Teresa, Giacco, Stefano Del, Heffler, Enrico, Grutta, Stefania La, Patella, Vincenzo, Ridolo, Erminia, Rolla, Giovanni, Rossi, Oliviero, Savi, Eleonora, Senna, Gianenrico, Tesi, Carlo Filippo, and Viegi, Giovanni
Subjects: lcsh:Immunologic diseases. Allergy, Allergy, medicine.medical_specialty, Immunology, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Pets exposure, Allergic rhinitis, Allergic sensitization, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Epidemiology, Allergic rhiniti, Dog, Hypersensitivity, medicine, Immunology and Allergy, 030212 general & internal medicine, Allergic rhinitis, Allergic sensitization, Bronchial asthma, Cat, Dog, Hypersensitivity, Pets, Pets exposure, Immunology and Allergy, Immunology, Molecular Biology, Bronchial asthma, Molecular Biology, Cat, Pets, Anamnesis, CATS, Modalities, business.industry, Research, medicine.disease, Pet ownership, Pet, 030228 respiratory system, Multicenter study, lcsh:RC581-607, business
Abstract: Background The query “are there animals at home?” is usually administered for collecting information on anamnesis. This modality to consider exposure to pet allergens constitutes a potential bias in epidemiological studies and in clinical practice. The aim of our study was to evaluate/quantify different modalities of exposure to cat/dog in inducing allergic sensitization. Methods Thirty Italian Allergy units participated in this study. Each centre was required to collect the data of at least 20 consecutive outpatients sensitized to cat/dog allergens. A standardized form reported all demographic data and a particular attention was paid in relieving possible modalities of exposure to cat/dog. Results A total 723 patients sensitized to cat/dog were recorded, 359 (49.65%) reported direct pet contact, 213 patients (29.46%) were pet owners, and 146 subjects (20.19%) were exposed to pets in other settings. Other patients were sensitized by previous pet ownership (150–20.75%) or indirect contact (103–14.25%), in 111 subjects (15.35%) any contact was reported. Conclusions Only 213 patients (29.46%) would be classified as “exposed to animals” and 510 (70.54%) as “not exposed” according to usual query. Our classification has shown that many “not-exposed” subjects (399–55.19%) were “really exposed”. The magnitude of exposure to pet allergens at home is not related exclusively to pet ownership. These considerations should be taken into account during the planning of epidemiological studies and in clinical practice for the management of pet allergic individuals.
Published: 2018

35. ARIA pharmacy 2018: Allergic rhinitis care pathways for community pharmacy

Author: Bosnic-Anticevich, Sinthia, Costa, Elísio, Menditto, Enrica, Lourenço, Olga, Novellino, Ettore, Bialek, Slawomir, Briedis, Vitalis, Buonaiuto, Roland, Chrystyn, Henry, Cvetkovski, Biljana, Di Capua, Stefania, Sousa, Jaime Correia de, De Carlo, Giuseppe, Demoly, Pascal, Devillier, Philippe, Dykewicz, Mark S, Gaga, Mina, El-Gamal, Yehia, Fonseca, João, Fokkens, Wytske J, Kuna, Piotr, Kowalski, Marek, Guzmán, Maria Antonieta, Haahtela, Tari, Hellings, Peter W, Illario, Maddalena, Ivancevich, Juan Carlos, Just, Jocelyne, Kaidashev, Igor, Khaitov, Musa, Khaltaev, Nikolai, Keil, Thomas, Larenas-Linnemann, Désirée, Kvedariene, Violeta, Klimek, Ludger, Laune, Daniel, Le, Lan T T, Lodrup Carlsen, Karin C, Mahboub, Bassam, Maier, Dieter, Malva, João, Manning, Patrick J, Okamoto, Yoshitaka, Ohta, Ken, Almeida, Mário Morais, Mösges, Ralph, Mullol, Joaquim, Münter, Lars, Murray, Ruth, Naclerio, Robert, Namazova-Baranova, Leyla, Nekam, Kristof, Nyembue, Tshipukane Dieudonné, Okubo, Kimi, Palkonen, Susanna, Onorato, Gabrielle L, O'Hehir, Robyn E, Panzner, Petr, Papadopoulos, Nikolaos G, Park, Hae-Sim, Pawankar, Ruby, Pfaar, Oliver, Phillips, Jim, Plavec, Davor, Stellato, Cristiana, Somekh, David, Popov, Todor A, Potter, Paul C, Prokopakis, Emmanuel P, Roller-Wirnsberger, Regina E, Rottem, Menachem, Ryan, Dermot, Samolinski, Boleslaw, Sanchez-Borges, Mario, Schunemann, Holger J, Sheikh, Aziz, Todo-Bom, Ana Maria, To, Teresa, Sisul, Juan Carlos, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Valero, Antonio, Valiulis, Arunas, Valovirta, Errka, Ventura, Maria Teresa, Wagenmann, Martin, Kritikos, Vicky, Bousquet, Jean, Wallace, Dana, Waserman, Susan, Wickman, Magnus, Yiallouros, Panayiotis K, Yorgancioglu, Arzu, Yusuf, Osman M, Zar, Heather J, Zernotti, Mario E, Zhang, Luo, Zidarn, Mihaela, Orlando, Valentina, Mair, Alpana, Zuberbier, Torsten, Paulino, Ema, Salimäki, Johanna, Söderlund, Rojin, Tan, Rachel, Williams, Dennis M, Wroczynski, Piotr, Agache, Ioana, Ansotegui, Ignacio J, Cruz, Alvaro A, Anto, Josep M, Bedbrook, Anna, Bachert, Claus, Bewick, Mike, Bindslev-Jensen, Carsten, Brozek, Jan L, Canonica, Giorgio Walter, Cardona, Victoria, Carr, Warner, Casale, Thomas, Czarlewski, Wienczyslawa, Chavannes, Niels H, and uBibliorum
Subjects: Care pathways, Pharmacist, Allergic Rhinitis and its Impact on Asthma, Asthma, Rhinitis
Abstract: Pharmacists are trusted health care professionals. Many patients use over-the-counter (OTC) medications and are seen by pharmacists who are the initial point of contact for allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The Allergic Rhinitis and its Impact on Asthma (ARIA)-pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses), and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of allergic rhinitis. However, the ARIA-pharmacy ICP should be adapted to local healthcare environments/situations as regional (national) differences exist in pharmacy care.
Published: 2019

36. Bronchodilator reversibility in asthma and COPD: Findings from three large population studies

Author: Janson, Christer, Malinovschi, Andrei, Amaral, Andre, Accordini, Simone, Bousquet, Jean, Buist, A Sonia, Canonica, Giorgio Walter, Dahlén, Barbro, Garcia-Aymerich, Judith, Gnatiuc, Louisa, Kowalski, Marek, Patel, Jaymini, Tan, Wan, Torén, Kjell, Zuberbier, Torsten, Burney, Peter, Jarvis, Deborah, Amaral, Andre F.S., Buist, A. Sonia, Commission of the European Communities, Wellcome Trust, Medical Research Council (MRC), Kaiser Foundation Hospitals,Center for Health Research, Sociedade Portuguesa de Pneumologia, Tartu University Hospital, Ciro Horn, Department of Medical Sciences, Respiratory Medicine & Allergology, Uppsala University, Population Health and Occupational Disease [Londres, Royaume-Uni], National Heart and Lung Institute [Londres, Royaume-Uni] (NHLI), Imperial College London-Imperial College London, Department of Diagnostics and Public Health [Verona] (UNIVR | DDSP), University of Verona (UNIVR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], University of British Columbia (UBC), Sahlgrenska Academy at University of Gothenburg, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), and Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: Male, Internationality, Respiratory System, ECRHS, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, RESPONSIVENESS, Pulmonary Disease, Chronic Obstructive, FEV1, 0302 clinical medicine, Forced Expiratory Volume, Bronchodilator, 030212 general & internal medicine, 11 Medical and Health Sciences, Aged, 80 and over, COPD, education.field_of_study, medicine.diagnostic_test, Middle Aged, respiratory system, Bronchodilator Agents, 3. Good health, TIME, LUNG-FUNCTION, Female, medicine.symptom, Life Sciences & Biomedicine, Adult, Pulmonary and Respiratory Medicine, Spirometry, medicine.medical_specialty, Adolescent, medicine.drug_class, prevalence, Population, GA2LEN, Young Adult, 03 medical and health sciences, FEV1/FVC ratio, Internal medicine, Wheeze, Administration, Inhalation, NITRIC-OXIDE LEVELS, medicine, Humans, Albuterol, VALIDITY, education, Aged, Asthma, Science & Technology, business.industry, asthma, BOLD, bronchodilator reversibility, COPD, ECRHS, GA2LEN, prevalence, asthma, medicine.disease, FVC, respiratory tract diseases, bronchodilator reversibility, Logistic Models, 030228 respiratory system, Multivariate Analysis, Exhaled nitric oxide, OBSTRUCTION, business, BOLD
Abstract: Bronchodilator response (BDR) testing is used as a diagnostic method in obstructive airway diseases. The aim of this investigation was to compare different methods for measuring BDR in participants with asthma and chronic obstructive pulmonary disease (COPD) and to study to the extent to which BDR was related to symptom burden and phenotypic characteristics.Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were measured before and 15 min after 200 μg of salbutamol in 35 628 subjects aged ≥16 years from three large international population studies. The subjects were categorised in three groups: current asthma (n=2833), COPD (n=1146) and no airway disease (n=31 649). Three definitions for flow-related reversibility (increase in FEV1) and three for volume-related reversibility (increase in FVC) were used.The prevalence of bronchodilator reversibility expressed as increase FEV1 ≥12% and 200 mL was 17.3% and 18.4% in participants with asthma and COPD, respectively, while the corresponding prevalence was 5.1% in those with no airway disease. In asthma, bronchodilator reversibility was associated with wheeze (OR 1.36, 95% CI 1.04–1.79), atopy (OR 1.36, 95% CI 1.04–1.79) and higher exhaled nitric oxide fraction, while in COPD neither flow- nor volume-related bronchodilator reversibility was associated with symptom burden, exacerbations or health status after adjusting for pre-bronchodilator FEV1.Bronchodilator reversibility was at least as common in participants with COPD as those with asthma. This indicates that measures of reversibility are of limited value for distinguishing asthma from COPD in population studies. However, in asthma, bronchodilator reversibility may be a phenotypic marker.
Published: 2019

37. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy'

Author: Yiallouros, Panayiotis K., Larenas‐Linnemann, Désirée E., Bosnic‐Anticevich, Sinthia, Costa, Elisio, Menditto, Enrica, Lourenço, Olga, Novellino, Ettore, Bialek, Slawomir, Briedis, Vitalis, Buonaiuto, Roland, Chrystyn, Henry, Cvetkovski, Biljana, Capua, Stefania Di, Kritikos, Vicky, Mair, Alpana, Orlando, Valentina, Paulino, Ema, Salimäki, Johanna, Söderlund, Rojin, Tan, Rachel, Williams, Dennis M., Wroczynski, Piotr, Agache, Ioana, Ansotegui, Ignacio J., Anto, Josep M., Bedbrook, Anna, Bachert, Claus, Bewick, Mike, Bindslev‐Jensen, Carsten, Brozek, Jan L., Canonica, Giorgio Walter, Cardona, Victoria, Carr, Warner, Casale, Thomas B., Chavannes, Niels H., Sousa, Jaime Correia de, Cruz, Alvaro A., Czarlewski, Wienczyslawa, Carlo, Giuseppe De, Demoly, Pascal, Devillier, Philippe, Dykewicz, Mark S., Gaga, Mina, El‐Gamal, Yehia, Fonseca, João, Fokkens, Wytske J., Guzmán, Maria Antonieta, Haahtela, Tari, Hellings, Peter W., Illario, Maddalena, Ivancevich, Juan Carlos, Just, Jocelyne, Kaidashev, Igor, Khaitov, Musa, Khaltaev, Nikolai, Keil, Thomas, Klimek, Ludger, Kowalski, Marek L., Kuna, Piotr, Kvedariene, Violeta, Laune, Daniel, Le, Lan T. T., Carlsen, Karin C. Lodrup, Mahboub, Bassam, Maier, Dieter, Malva, Joao, Manning, Patrick J., Morais‐Almeida, Mário, Mösges, Ralph, Mullol, Joaquim, Münter, Lars, Murray, Ruth, Naclerio, Robert, Namazova‐Baranova, Leyla, Nekam, Kristof, Nyembue, Tshipukane Dieudonné, Okubo, Kimi, O'Hehir, Robyn E., Ohta, Ken, Okamoto, Yoshitaka, Onorato, Gabrielle L., Palkonen, Susanna, Panzner, Petr, Papadopoulos, Nikolaos G., Park, Hae-Sim, Pawankar, Ruby, Pfaar, Oliver, Phillips, Jim, Plavec, Davor, Popov, Todor A., Potter, Paul C., Prokopakis, Emmanuel P., Roller‐Wirnsberger, Regina E., Rottem, Menachem, Ryan, Dermot, Samolinski, Bolesław, Sanchez‐Borges, Mario, Schunemann, Holger J., Sheikh, Aziz, Sisul, Juan Carlos, Somekh, David, Stellato, Cristiana, To, Teresa, Todo‐Bom, Ana Maria, Tomazic, Peter Valentin, Toppila‐Salmi, Sanna, Valero, Antonio, Valiulis, Arunas, Valovirta, Errka, Ventura, Maria Teresa, Wagenmann, Martin, Wallace, Dana, Waserman, Susan, Wickman, Magnus, Yorgancioglu, Arzu, Yusuf, Osman M., Zar, Heather J., Zernotti, Mario E., Zhang, Luo, Zidarn, Mihaela, Zuberbier, Torsten, Bousquet, Jean, Yiallouros, Panayiotis K. [0000-0002-8339-9285], Costa, Elisio [0000-0003-1158-1480], Kritikos, Vicky [0000-0003-3955-0002], Gaga, Mina [0000-0002-9949-6012], Papadopoulos, Nikolaos G. [0000-0002-4448-3468], and Prokopakis, Emmanuel P. [0000-0002-1208-1990]
Abstract: Pharmacists are trusted health care professionals. Many patients use over-the-counter (OTC) medications and are seen by pharmacists who are the initial point of contact for allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The Allergic Rhinitis and its Impact on Asthma (ARIA)-pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses), and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of allergic rhinitis. However, the ARIA-pharmacy ICP should be adapted to local healthcare environments/situations as regional (national) differences exist in pharmacy care. 74 7 1219 1236
Published: 2019

38. Alergijski rinitis in njegov vpliv na astmo (ARIA)-glavni povzetek 2016: ARIA 2016 executive summary: integrated care pathways for predictive medicine across the life cycle: integrirane klinične poti za napovedno medicino v vseh življenjskih obdobjih

Author: Agache, Ioana, Bachert, Claus, Bajrović, Nisera, Bedbrook, Anna, Bousquet, Jean, Canonica, Giorgio Walter, Casale, Thomas, Cruz, Alvaro A., Edelbaher, Natalija, Fokkens, Wytske J., Hellings, Peter W., Jenko, Klemen, Jošt, Maja, Kopač, Peter, Koren, Anja, Košnik, Mitja, Kramer Vrščaj, Karmen, Kreft, Samo, Lalek, Nika, Madjar, Bojan, Poplas-Susič, Tonka, Rozman Sinur, Irma, Samolinski, Boleslaw, Soklič, Tanja, Triller, Katja, Triller, Nadja, Urbančič, Jure, and Zidarn, Mihaela
Published: 2019

39. MOESM1 of Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis

Author: Mullol, Joaquim, Izquierdo, Iñaki, Okubo, Kimihiro, Canonica, Giorgio, Bousquet, Jean, and Valero, Antonio
Abstract: Additional file 1: Table S1. Characteristics of rupatadine clinical studies included in the pooled analysis. Table S2. Effects of rupatadine treatment on total nasal symptom (T4NSS), ocular symptom (T2OSS), and total symptom (T6SS) scores.
Published: 2019
Full Text: View/download PDF

40. ARIA (Allergic Rhinitis and its Impact on Asthma) 2019. Percorsi di cura per la rinite allergica -ITALIA

Author: Passalacqua, Giovanni, Cecchi, Lorenzo, Canonica, Giorgio Walter, Lombardi, Carlo, Ventura, Maria Teresa, Bachert, Claus, Wystke J Fokkens, Tari Haahtela, Klimek, Ludger, Berlin Berlin, Arasi, Stefania, Bagnasco, Diego, Baiardini, Ilaria, Bernardini, Roberto, Bilò, Maria Beatrice, Bonini, Sergio, G Walter Canonica, Canevari, Rikki F, Caviglia, Antonio, Enrico 39 Compalati, Cottini, Marcello, Mariangiola Crivellaro, Duse, Marzia, Fiocchi, Alessandro, Folletti, Gelardi, Matteo, Heffler, Enrico, Incorvaia, Cristoforo, Infantino, Antonio, Leo, Gualtiero, Maggi, Enrico, Marseglia, Gianluigi, Melioli, Giovanni, Milanese, Manlio, Musarra, Antonino, Nettis, Eustachio, Pajno, Giovanni, Pala, Gianni, Peroni, Diego, Ridolo, Rolla, Giovanni, Rossi, Oliviero, Savi, Eleonora, Senna, Gianenrico, Tesi, Filippo, Triggiani, Massimo, Uberti, Marzio, Zedda, Maria Teresa, and Landi, Massimo
Published: 2019
Full Text: View/download PDF

41. Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI

Author: Senna, Gianenrico, Latorre, Manuela, Bugiani, Massimo, Caminati, Marco, Heffler, Enrico, Morrone, Daniela, Paoletti, Giovanni, Parronchi, Paola, Puggioni, Francesca, Blasi, Francesco, Canonica, Giorgio Walter, Paggiaro, Pierluigi, Sani, Network, Bacci, E., Bonavia, M., Caiaffa, P., Calabrese, C., Camiciottoli, G., Caruso, C., Centanni, S, Conte, Me., Corsico, Ag., Cosmi, L., Costantino, Mt., Crimi, N., D'Alò, S., D'Amato, M., Del Giacco, S., Favero, E., Farsi, A., Foschino, Bpm., Guarnieri, G., Guida, G., Lombardi, C., Macchia, L., Menzella, F., Milanese, M., Montuschi, P., Nucera, E., Parente, R., Passalacqua, G., Patella, V., Pelaia, G., Pini, L., Ricciardolo, Flm., Ricciardi, L., L. Richeldi, E, Ridolo, Rolla, G., Santus, P., Scichilone, N., Solidoro, P., Spadaro, G., Spanevello, A., Vianello, A., Yacoub, Mr., and Zappa, Mc.
Subjects: Pulmonary and Respiratory Medicine, Severe asthma, obesity, medicine.medical_specialty, Multivariate analysis, Immunology, Disease, Immunoglobulin E, smoking, 03 medical and health sciences, 0302 clinical medicine, male, Internal medicine, Female patient, sex, Immunology and Allergy, Medicine, 030223 otorhinolaryngology, Asthma, biology, business.industry, biomarkers, female, type 2, medicine.disease, Obesity, 030228 respiratory system, Exhaled nitric oxide, biology.protein, Original Article, business
Abstract: Purpose After adolescence, asthma is more frequent in females than in males due to different hormonal, immunologic, and occupational/environmental factors. The higher prevalence and severity of the disease in females have already been reported in international registries. The aim of this study was to explore the difference in terms of clinical, functional, and biological characteristics between male and female patients with severe asthma in a real-life, registry-based setting. Methods Baseline data from the Severe Asthma Network in Italy registry were analyzed in 1,123 patients with severe asthma, according to sex. Results Almost 2/3 of severe asthmatics were female. Late-onset asthma, obesity and gastro-esophageal reflux were more frequent in females than in males, while previous smoking habits and nasal polyposis were more frequent in males. Females had poor asthma control and a higher number of severe exacerbations leading to hospitalization, in comparison to males. Biomarkers of type 2 inflammation (blood eosinophil, exhaled nitric oxide, and serum immunoglobulin E levels) were significantly higher in males than in females. The type 2 profile (defined by a combination of these 3 biomarkers) was significantly more frequent in males than in females. In multivariate analysis, late-onset asthma and a normal body mass index were only independent variables associated with the type 2 profile, while male sex and age showed only a trend toward the association with the type 2 profile. Conclusions Significant differences may be observed between male and female patients with severe asthma, influencing the asthma pheno-endotyping in both sexes.
Published: 2021

42. ARIA Phase 4 (2018): change management in allergic rhinitis and asthma multimorbidity using mobile technology

Author: Bousquet, J., Hellings, Peter W., Agache, Ioana, Amat, F., Annesi-Maesano, I., Ansotegui, I. J., Anto, J. M., Bachert, C., Bateman, Eric D., Bedbrook, A., Bennoor, Kazi S., Bewick, M., Bindslev-Jensen, Carsten, Bosnic-Anticevich, Sinthia Z., Bosse, Isabelle, Brozek, Jan, Brussino, Luisa, Canonica, Giorgio W., Cardona, Victòria, Casale, Thomas, Cepeda Sarabia, Alfonso M., Chavannes, Niels H., Cecchi, Lorenzo, Correia de Sousa, Jaime, Costa, Elisio, Cruz, A. A., Czarlewski, Wienczyslawa, De Carlo, Giuseppe, De Feo, G., Demoly, Pascal, Devillier, P., Dykewicz, Mark S., El-Gamal, Yehia, Eller, Esben, Fonseca, J., Fontaine, J. F., Fokkens, W. J., Guzmán, Maria-Antonieta, Haahtela, Tari, Illario, Magdalena, Ivancevich, Juan-Carlos, Just, Jocelyne, Kaidashev, Igor, Khaitov, Musa, and Hourihane, Jonathan O'B.
Subjects: animal structures, ARIA, Change management, Asthma, Rhinitis
Abstract: Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best approach to integrated care pathways (ICPs) using mobile technology in AR and asthma multimorbidity. The proposed next phase of ARIA is Change Management (CM) with the aim of providing an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle whatever their gender or socio-economic status in order to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the impact of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of IT evidence-based tools (MASK: Mobile Airways Sentinel Network) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional.
Published: 2018

43. Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria

Author: Folci, Marco, Heffler, Enrico, Canonica, Giorgio W., Furlan, Raffaello, and Brunetta, Enrico
Subjects: Article Subject
Abstract: Chronic spontaneous urticaria (CSU) is defined by the appearance of wheals and a variable presence of angioedema which persists for at least 6 weeks. It represents the most common subtype of chronic urticaria and is gaining importance in civil society because of its association with impaired quality of life. Moreover, CSU has a growing impact on national health systems representing a great burden due to its variable rate of response to the approved therapies. In this scenario, the identification of clinical and molecular biomarkers is of pivotal importance. Some groups are trying to detect molecules which would be able to help clinicians in reaching a proper diagnosis; additionally, the opportunity to describe disease severity which leads to cluster patients in different groups could fill the gap in the numerous unmet clinical needs. Several biomarkers are currently being studied with the purpose to predict the response to a defined therapy; unfortunately, none of them are ready to be translated from bench to bedside.
Published: 2018
Full Text: View/download PDF

44. Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma

Author: Bagnasco, Diego, Caminati, Marco, Ferrando, Matteo, Aloè, Teresita, Testino, Elisa, Canonica, Giorgio Walter, and Passalacqua, Giovanni
Subjects: Article Subject
Abstract: The current developments of the new biological drugs targeting interleukin 5 (IL-5) and IL-5 receptor allowed to expand the treatment options for severe hypereosinophilic asthma. Clinicians will then be able to choose between antibodies targeting either circulating IL-5 or its receptor expressed on eosinophils and basophils. The available clinical trials consistently reported favorable results about the reduction of exacerbations rate, improvement in quality of life, and sparing of the systemic steroid use, with a favorable safety profile. Two of these new drugs are administered subcutaneously, mepolizumab every 4 weeks and benralizumab every 8 weeks, whereas reslizumab is given intravenously monthly on a weigh-based dose. In the future, the research actions will be involved in the identification of a single biomarker or multiple biomarkers for the optimal choice of biological agents to be properly prescribed.
Published: 2018
Full Text: View/download PDF

45. Omalizumab for Idiopathic Nonhistaminergic Angioedema: Evidence for Efficacy in 2 Patients

Author: Brunetta, Enrico, Shiffer, Dana, Folci, Marco, Achenza, Maria I. S., Puggioni, Francesca, Heffler, Enrico, Furlan, Raffaello, and Canonica, Giorgio W.
Subjects: Article Subject
Abstract: Presently, there is inconclusive evidence regarding the most effective treatment for idiopathic nonhistaminergic acquired angioedema (InH-AAE). Omalizumab may, however, prove to be a promising option. This case report describes two patients who presented with recurrent angioedema attacks, which was refractory to antihistamine therapy. Hence, they were treated with 300 mg omalizumab, every 4 weeks, for a period of 6 months. Both patients had shown a rapid response to the treatment and achieved complete resolution of symptoms without further AE attacks throughout the entire duration of the treatment period. After omalizumab’s suspension, one patient remained symptom free for the following 6 months and the other patient had recurrence of symptoms after 2 months for which he was retreated with omalizumab and once again became symptom free. Although omalizumab seems to be effective as a prophylactic treatment for InH-AAE, the determining factors leading to the differences in time-to-relapse between patients after its suspension remain unclear. Further studies are needed in order to better determine the potential therapeutic application of omalizumab and its role in maintenance therapy.
Published: 2018
Full Text: View/download PDF

46. EAACI/GA2LEN/EDF/WAO-Leitlinie für die Definition, Klassifikation, Diagnose und das Management der Urtikaria — konsentierte, deutschsprachige Übersetzung

Author: Zuberbier, Torsten, Aberer, Werner, Asero, Riccardo, Latiff, Amir Hamzah Abdul, Baker, Diane, Ballmer-Weber, Barbara K, Bernstein, Jonathan A, Bindslev-Jensen, Carsten, Brzoza, Zenon, Bedrikow, Roberta Buense, Canonica, Giorgio Walter, Church, Martin K, Craig, Timothy, Danilycheva, Inna Vladimirovna, Dressler, Corinna, Ensina, Luis Felipe, Giménez-Arnau, Ana M, Godse, Kiran, Gonçalo, Margarida, E. H. Grattan, Clive, Hebert, Jacques, Hide, Michihiro, Kaplan, Allen, Kapp, Alexander, Katelaris, Constance H., Kocatürk, Emek, Kulthanan, Kanokvalai, Larenas-Linnemann, Desiree, Leslie, Tabi A., Magerl, Markus, Mathelier-Fusade, Pascale, Meshkova, Raisa Y., Metz, Martin, Nast, Alexander, Nettis, Eustachio, Oude-Elberink, Hanneke N G, Rosumeck, Stefanie, Saini, Sarbjit S, Sánchez-Borges, Mario, Schmid-Grendelmeier, Peter, Staubach, Petra, Sussman, Gordon, Toubi, Elias, Vena, Gino A., Vestergaard, Christian, Wedi, Bettina, Werner, Ricardo N., Zhao, Zuotao, Maurer, Marcus, Brehler, Randolf, Brockow, Knut, Fluhr, Joachim, Grabbe, Jürgen, Hamelmann, Eckard, Hartmann, Karin, Jakob, Thilo, Merk, Hans, Ollert, Markus, Ott, Hagen, Reese, Imke, Ruëff, Franziska, and Werfel, Thomas
Published: 2018

47. [ARIA 2016 executive summary: Integrated care pathways for predictive medicine throughout the life cycle in Argentina]

Author: Ivancevich, Juan Carlos, Neffen, Hugo, Zernotti, Mario E., Asayag, Estrella, Blua, Ariel, Ciceran, Alberto, Jares, Edgardo J., Lavrut, Alberto J., Maspero, Jorge F., Agache, Ioana, Bachert, Claus, Bedbrook, Anna, Canonica, Giorgio W., Casale, Thomas B., Cruz, Alvaro A., Fokkens, Wytske J., Peter Hellings, Samolinski, Boleslaw, Bousquet, Jean, Ghent University Hospital, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Medical University of Warsaw - Poland, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
Subjects: lcsh:Immunologic diseases. Allergy, EIP on AHA, Visual Analog Scale, [SDV]Life Sciences [q-bio], Tecnologías de la Información y la Comunicación, Clinical Decision-Making, Argentina, World Health Organization, Iniciativa ARIA, Medical Records, User-Computer Interface, Surveys and Questionnaires, Mobile technology, Tecnología móvil, Humans, Healthcare Disparities, Airways ICPs, Rinitis, Rhinitis, Vías de atención integradas para las enfermedades de las vías respiratorias, Delivery of Health Care, Integrated, Health Plan Implementation, Disease Management, Mobile Applications, Rhinitis, Allergic, Asthma, ARIA initiative, Asociación Europea de Innovación para un Envejecimiento Activo y Saludable, ICT, Smartphone, lcsh:RC581-607
Abstract: The ARIA initiative was started during a World Health Organization workshop in 1999. The initial goals were to propose a new classification for allergic rhinitis, to promote the concept of multi-morbidity in asthma and rhinitis and to develop guidelines with stakeholders for world-wide use. ARIA is now focused on the implementation of emerging technologies for individualized and predictive medicine. MASK: MACVIA-Aria Sentinel Network uses mobile technology to develop care pathways that enable management by a multidisciplinary group or by patients themselves. An App for iOS and Android uses a visual analogue scale to assess symptom control and work productivity, as well as a clinical decision support system; it is associated with an interoperable tablet for health professionals. The escalation strategy uses recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of ARIA's new approach is to provide an active and healthy life to people affected by rhinitis, regardless of age, gender or socioeconomic status, in order to reduce social and health inequalities caused by the disease.La iniciativa ARIA (Rinitis Alérgica y su Impacto en el Asma) se inició durante un taller de la Organización Mundial de la Salud en 1999. Los objetivos iniciales fueron proponer una nueva clasificación de rinitis alérgica, promover el concepto de multimorbilidad en asma y rinitis y desarrollar guías con todas las partes interesadas para su en todos los países y poblaciones. ARIA, difundida e implementada en más de 70 naciones, ahora se centra en la implementación de tecnologías emergentes para la medicina individualizada y predictiva. MASK (MACVIA [Contre les Maladies Chroniques pour un Vieillissement Actif] Aria Sentinel Network) utiliza la tecnología móvil para desarrollar vías de atención que permitan el manejo de la rinitis y del asma por un grupo multidisciplinario o por los propios pacientes. Una aplicación (app) para iOS y Android está disponible en 20 países y 15 idiomas; utiliza una escala analógica visual para evaluar el control de los síntomas y la productividad del trabajo, así como un sistema de apoyo para las decisiones clínicas. Se asocia con una tabla interoperable (que permite intercambiar información) para médicos y otros profesionales de la salud. La estrategia de escalamiento utiliza las recomendaciones de la Asociación Europea de Innovación para el Envejecimiento Activo y Saludable. El objetivo del nuevo enfoque ARIA es proporcionar una vida activa y saludable a las personas afectadas por la rinitis, cualquiera que sea su edad, sexo o condición socioeconómica, con el fin de reducir las desigualdades sociales y de salud causadas por la enfermedad.
Published: 2017

48. Validation of the Global Allergy and Asthma European Network (GA 2 LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber

Author: Zuberbier , Torsten, Abelson , Mark, Akdis , Cezmi, Bachert , Claus, Berger , Uwe, Bindslev-Jensen , Carsten, Boelke , Georg, Bousquet , Jean, Canonica , Giorgio Walter, Casale , Thomas, Jutel , Marek, Kowalski , Marek, Madonini , Enzo, Papadopoulos , Nikolaos, Pfaar , Oliver, Sehlinger , Torsten, Bergmann , Karl-Christian, European Union Network of Excellence in Allergy and Asthma , Global Allergy and Asthma European Network (GA(2)LEN), and Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier )
Subjects: validation, Global Allergy and Asthma European Network (GA(2)LEN), [ SDV.IMM.ALL ] Life Sciences [q-bio]/Immunology/Allergology, grasses, placebo, Allergy trial, environmental exposure chamber
Abstract: International audience; BACKGROUND:Field clinical trials of pollen allergy are affected by the impossibility of predicting and determining individual allergen exposure because of many factors (eg, pollen season, atmospheric variations, pollutants, and lifestyles). Environmental exposure chambers, delivering a fixed amount of allergen in a controlled environmental setting, can overcome these limitations. Environmental exposure chambers are currently already used in phase 2, 3, and even 4 trials. Unfortunately, few chambers exist in the world, and this makes it difficult to perform large, multicenter clinical trials. The new Global Allergy and Asthma European Network (GA2LEN) mobile exposure chamber is a step forward because the mobility of the chamber makes it convenient for patients to participate in clinical testing.OBJECTIVE:This study was made to validate the reproducibility, sensitivity, and specificity of the results obtained in the new GA2LEN chamber.METHODS:Seventy-two adult patients (19-61 years old) with allergic rhinitis with or without asthma caused by grass pollen were included in different clinical validation tests. Total symptom scores and total nasal symptom scores were recorded at time zero (0) and every 10 minutes during exposures, along with nasal and respiratory parameters.RESULTS:Exposure tests confirmed the reproducibility between subsequent runs and the sensitivity (P < .00001 vs patients exposed to placebo) and specificity (very low score in nonallergic subjects) in the GA2LEN chamber. No adverse reactions were recorded during the tests.CONCLUSIONS:The mobility of the GA2LEN chamber provides a new, potentially effective, and safe way of generating reliable data in allergy multicenter clinical trials.
Published: 2017

49. MOESM1 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â months

Author: Riccio, Anna, Mauri, Pierluigi, Ferrari, Laura, Rossi, Rossana, Silvestre, Dario Di, Benazzi, Louise, Chiappori, Alessandra, Negro, Roberto Dal, Micheletto, Claudio, and Canonica, Giorgio
Subjects: sense organs, skin and connective tissue diseases
Abstract: Additional file 1. Natural logarithm (ln) of fold change between baseline (T0) and long term anti-IgE treatment (T36) for each subject. Significant values (ln[Fold Change]>|0.6| are are reported in red or blue: positive (blue) and negative (red) values indicate increase and decrease at T36, respectively. Specifically, for ln(Fold Change) >0.6 (blue) increase at T36; on the contrary, if it is
Published: 2017
Full Text: View/download PDF

50. MOESM6 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â months

Author: Riccio, Anna, Mauri, Pierluigi, Ferrari, Laura, Rossi, Rossana, Silvestre, Dario Di, Benazzi, Louise, Chiappori, Alessandra, Negro, Roberto Dal, Micheletto, Claudio, and Canonica, Giorgio
Abstract: Additional file 6. Differential Analysis (DAVE index) between baseline (T0) and long term anti-IgE treatment (T36) for each subject, using DAVE index from MAPROMA software [9]. Significant values (DAVE > |0.4|) are reported in red or blue: positive (blue) and negative (red) values indicate increase and decrease at T36, respectively. SMPs: smooth muscle proteins. Of note, DAVE algorithm, tpical of proteomics evaluation, was also applied to eosinophils; the obtained values resulted in good agreement with evaluation obtained by ln[T36/T0] (see also Additional file 1 and compare Fig. 2 and Additional file 4). * p-value; T-test2 is without NOR2 subject, because at T36 its behaviour is similar to ORs (see Fig. 6); in bold significant T-tests.
Published: 2017
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

242 results on '"Canonica, Giorgio"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources